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CHAPTER I 
 
 
INTRODUCTION 
 
Background 
Vitamin D is well established for maintaining calcium homeostasis and preserving 
skeletal health (1,2). The major source of vitamin D is derived through cutaneous 
synthesis following exposure to ultraviolet light from the sun. Diet has become an 
alternative approach for humans to meet their vitamin D requirements (3,4). Although 
vitamin D synthesis is initiated from the skin, the synthesis of the active form of vitamin 
D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is completed in the kidney. This active 
form of vitamin D exerts its effects on target tissues such as bone, intestine, and immune 
cells primarily through the nuclear hormone vitamin D receptor (VDR) (4-6). Vitamin D 
binding proteins (DBPs) are vitamin D metabolite carriers in the serum. The regulation of 
vitamin D metabolism can be affected at the gene transcription level. Functionally, 
vitamin D has been shown to have protective effect on bone, cardiovascular, and immune 
system (1,7-10). 
Serum 25-(OH)D3 is an indicator of systemic vitamin D status. It is used as 
measure of vitamin D status, however, the levels used to define deficiency, insufficiency, 
or optimal vitamin D status remain controversial (11,12). According to Whiting and 
Calvo, serum 25-(OH)D3 less than 30 nmol/L is defined as vitamin D deficiency, 
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insufficiency ranges from 40-80 nmol/L, and 90-120 nmol/L serum 25-(OH)D3 is defined 
as the optimal (12). In contrast, Zittermann and colleagues (13) defined vitamin D 
deficiency as 0-25 nmol/L, insufficiency as 25-50 nmol/L, hypovitaminosis as 50-70 
nmol/L, adequacy as 70-250 nmol/L, toxicity as >250 nmol/L.  
Deficiency of vitamin D is not only found in populations living in low ambient 
UV environments, for instance in the northern part of the United States (6,14,15), Canada 
(16), France (17), Ireland (18), and New Zealand (19), but it is also found in populations 
living in the sunny countries such as Australia, Africa, India and Pakistan (20). 
Populations from these countries may be deficient in vitamin D due to insufficient sun 
exposure, clothing habits, hyper-pigmentation, air pollution which prevent ultraviolet 
(UVB) exposure to skin as well as insufficient intake of vitamin D (21). Further, 
Awumey and colleagues (22) showed that fibroblasts of Indian-Americans had higher 
activity level of 24-hydroxylase (24-OHase) compared to controls, suggesting the 
increased to vitamin D catabolism may contribute to vitamin D deficiency. At risk 
populations for vitamin D deficiency include the elderly (1,23,24), those with darkly 
pigmented skin (25), hospitalized patients (24), and women receiving anti-osteoporotic 
therapy (15). Vitamin D deficiency is often related to rickets in children (16,26), 
however, osteoporosis (27), cardiovascular disease, certain cancers, type 1 and type 2 
diabetes mellitus are diseases associated with vitamin D deficiency in adults and the 
elderly (28,29).  
The benefits of vitamin D to bone have been well established. Vitamin D prevents 
(2) and reduces (30) the risk of hip fracture when calcium supplementation is added. Zhu 
and colleagues (31) showed that a combination of vitamin D and calcium 
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supplementation is effective in reducing bone turnover rate in elderly women living in a 
sunny climate. Further, vitamin D combined with calcium supplementation has been 
shown to reduce the risk of falls in older women (32). A randomized controlled trial in 
adults showed that daily vitamin D supplementation ≥800 IU reduced risk of hip fracture 
and nonvertebral fracture compared with calcium and placebo (33).  
Renal production of 1,25(OH)2D3 is regulated by parathyroid hormone (PTH), 
serum calcium and phosphorous (34). The relationship between 25-(OH)D3 and PTH is 
considered to be inverse (35,36). Low serum 25-(OH)D3 in response to elevated PTH 
could result in accelerated bone turnover which may lead to bone loss, osteoporosis, and 
fracture (36-39). The decrease in vitamin D may be attributed to decreased expression of 
renal 1-α hydroxylase (1α-OHase) (40). As renal function deteriorates, the body fails to 
maintain proper calcium and phosphorous balance. The disturbances in calcium and 
phosphorous metabolism cause parathyroid glands to secrete excess PTH, which leads to 
secondary hyperparathyroidism (SPTH) (23). SHPT is responsible for decreased bone 
mineral density (BMD) and increased bone turnover, fractures, bone pain, marrow 
fibrosis and eventual erythropoietin resistance in kidney patients (21). SHPT associated 
with vitamin D deficiency also increases the risk of fracture, particularly femoral neck 
fracture (29). 
In addition to protecting the bone and cardiovascular system, vitamin D has 
various effects on cellular proliferation and on immune function (10). Many of the 
biological effects of vitamin D are mediated through the vitamin D receptor (VDR) (41) 
which are present in most of the cells of the immune system, including the activated T- 
and B-lymphocytes, macrophages, and dendritic cells (4,42). Both macrophages and 
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dendritic cells can act as antigen presenting cells (APCs), however, dendritic cells are the 
primary APCs responsible for T-lymphocytes activation (43) compared to macrophages 
(44). Furthermore, as macrophages and dendritic cells differentiate, they both 
demonstrate similar patterns of expression for cytochrome P450 family 27 (CYP27), the 
vitamin D activating enzyme, and VDR (43,44). Studies on vitamin D and autoimmune 
diseases showed that 1,25(OH)2D3 is an effective suppressor of inflammatory bowel 
disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes 
mellitus (45), and experimental autoimmune encephalomyelitis (46). 
Previously, a chronic low-grade inflammation model was developed in our 
laboratory to examine the effects of subclinical inflammation on bone loss (47). In the 
first study, chronic inflammation was induced in 3-month-old male Sprague-Dawley rats 
exposed to 90-days of lipopolysaccharide (LPS) and resulted in decreased bone mineral 
density (BMD) in femur and vertebra. Bone loss was primarily observed in the trabecular 
regions compared to the mid-diaphysis area which is primarily cortical bone. In addition 
to bone loss, over time LPS exposure in Sprague-Dawley rats fibrous tissue developed 
around the arterioles, consistent with vascular disease. Elevation of neutrophil and 
monocyte counts in peripheral blood was demonstrated over time and the up-regulation 
of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and cyclooxegenase (COX)-2 at 90 
days suggested an on-going inflammatory response. A subsequent study, was performed 
using adult male C57BL/6J mice and similar results were shown relative to the bone and 
vascular pathology as observed in the rat model (48). TNF-α was up-regulated in the 
same regions of the bone and vascular wall. Although chronic elevation of pro-
inflammatory mediators, bone loss and vascular pathology have been shown in this 
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animal model, it is not known if the pathology results from the direct effects of these 
inflammatory mediators alone or if their effects on other factors such as vitamin D status 
may play a role.  
Humans with inflammatory conditions such as inflammatory bowel disease (IBD) 
(49-52), type 1 and type 2 diabetes mellitus (53,54), RA were found to have 
compromised vitamin D status (55,56). TNF-α was one of the major contributors to the 
manifestation of these diseases which is found in the serum, synovial tissue and fluid (57-
60). Previous in vivo studies have indicated that the production of inflammatory 
cytokines (i.e., TNF-α) induced via slow-release LPS pellets was up-regulated in the 
cardiovascular wall and decreased trabecular bone (47,48). Thus, it is interesting to 
examine whether the up-regulation of TNF-α, as well as other inflammatory cytokines, 
alter local and/or systemic vitamin D metabolism.  
Therefore, the purpose of this study is to examine the extent to which chronic 
inflammation alters vitamin D metabolism. Due to the role of the kidney and liver in 
vitamin D synthesis and catabolism, we will examine the alterations in key genes 
encoding for vitamin D activating and deactivating enzyme, 1-α-hydroxylase (CYP27B1) 
and 24-hydroxylase (CYP24A1) in animals chronically exposed to LPS. Additionally, the 
spleen will be used as a site to examine local vitamin D metabolism due to its high 
monocytes content (61,62). It should be noted that monocytes/macrophages CYP27B1 
have been shown to produce 1,25(OH)2D3 in the late phase of activation, thus it seems 
that vitamin D has a local rather than systemic effect on monocytes/macrophages (41). 
The following hypotheses will be tested accomplish the overall purpose of this study. 
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Hypotheses (Experiment 1) 
1.   Over time (i.e., 30 and 90 days) chronic inflammation induced with increasing 
dose of LPS in adult C57BL/6J mice will alter genes encoding for vitamin D 
activating and deactivating enzyme, 1-α-hydroxylase (CYP27B1) and 24-
hydroxylase (CYP24A1), in hepatic tissue.  
2.   LPS will dose dependently reduce circulating vitamin D metabolite (25-(OH)D3) 
in adult male C57BL/6J mice over time.  
3.   LPS-induced pro-inflammatory cytokine (e.g. TNF-α) will down-regulate genes 
encoding vitamin D activating and deactivating enzymes in the spleen, a 
monocyte rich tissue, in adult male C57BL/6J mice.  
 
Hypotheses (Experiment 2) 
1.   Short-term (14-days) inflammation induced with increasing dose of LPS (0, 0.1  
or 0.2 mg LPS /kg body weight/day) in adult C57BL/6J mice will alter genes 
encoding for vitamin D activating and deactivating enzyme, 1-α-hydroxylase 
(CYP27B1) and 24-hydroxylase (CYP24A1), in hepatic and renal tissues.  
2.   LPS will dose dependently reduce circulating vitamin D metabolite (25-(OH)D3)  
in adult male C57BL/6J mice.  
3.   LPS-induced pro-inflammatory cytokine (e.g. TNF-α) will down-regulate genes 
encoding vitamin D activating and deactivating enzymes in the spleen, a 
monocyte rich tissue, in adult male C57BL/6J mice.  
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Objectives (Experiment 1) 
1.   To assess the relative abundance of mRNA of for genes encoding for vitamin D 
activating and deactivating enzymes in C57BL/6J mice, quantitative real-time 
PCR (qRT-PCR) will be used. RNA will be extracted from the liver and results 
will be expressed relative to controls.   
2.   To access circulating vitamin D metabolites, 25-(OH)D3 and 1,25(OH)2D3, in 
mice exposed to low-grade chronic inflammation in plasma using an enzyme-
linked immunoassays. 
3.   To determine relative expression of genes encoding for vitamin D activating and 
deactivating enzymes in the spleen, a monocyte rich tissue, using quantitative 
real-time PCR (qRT-PCR).  
 
Objectives (Experiment 2) 
1.   To assess genes encoding for vitamin D activating and deactivating enzymes in 
C57BL/6 mice using quantitative real-time PCR (qRT-PCR). RNA will be 
extracted from the liver and kidney and results will be expressed relative to 
controls.   
2.   To access circulating vitamin D metabolites, 25-(OH)D3 and 1,25(OH)2D3, in 
mice exposed to low-grade chronic inflammation in plasma, an enzyme-linked 
immunoassay will be used. 
3.   To determine relative expression of genes encoding for vitamin D activating and 
deactivating enzymes in the spleen, a monocyte rich tissue, quantitative real-time 
PCR (qRT-PCR) techniques will be used to examine the relative abundance.  
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Limitations 
  As with most scientific investigations, the experiments performed as a part of this 
overall project were not without limitations. For instance, experiment 1 was a previously 
conduced experiment that was not designed to address our questions on inflammation and 
vitamin D as described here. It was designed to examine the dose-dependent effects of 
subclinical inflammation on bone loss over time. Because of this, kidney samples were 
not procured in this experiment. We would have preferred to have kidney tissue from 
experiment 1, though we utilized tissue samples (i.e., liver and spleen) from the 
experiment to examine the relationship of inflammation and vitamin D.   
In experiment 1, we utilized slow release-pellets to deliver LPS subcutaneously. 
The amount of LPS delivered in experiment 1 was approximately 3 µg over 24 hours. In 
contrast, LPS that we used in experiment 2 was delivered via intraperitoneal injection. 
The amount of LPS delivered in experiment 2 was approximately 4 µg in a single dose. 
Therefore, the difference in the amount of LPS and the duration of the LPS release into 
the animals might cause variation in gene expression levels. Furthermore, a single dose of 
4 µg of LPS injection caused immediate and definite changes in the liver that might not 
be achievable with a slow-release pellet that was designed to deliver 3 µg of LPS over 24 
hours. Hence, in these studies, two different approaches to delivering LPS were utilized 
to examine the effects of chronic low-grade inflammation on vitamin D metabolism. Due 
to the different techniques of LPS delivery, we cannot compare the effects of LPS on key 
vitamin D hydroxylation enzymes and VDR expression between the two experiments. 
However, our data would provide insight into what effects occur at what methods of LPS 
delivery.  
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Another limitation in our study was that we only utilized one time point (14 days) 
in experiment 2. Thus, we could not address what would happen to the gene expression 
associated with key vitamin D hydroxylation enzymes and vitamin D levels after the two-
week time point. 
  
CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Introduction to Osteoporosis 
  Osteoporosis is defined as a skeletal disease characterized by a low bone mass 
and bone microarchitectural deterioration with a consequent increase in bone fragility and 
susceptibility to fracture (63). The World Health Organization (WHO) has established 
criteria for osteoporosis in postmenopausal women based on measurements of bone 
mineral density (BMD) expressed in terms of the number of standard deviations (SD) 
from the normal value or T score (64). The diagnostic categories are 1) normal T ≥ -1.0, 
2) osteopenia -2.5 < T < -1.0, 3) osteoporosis T ≤ -2.5, 4) established or severe 
osteoporosis T ≤ -2.5 in the presence of one or more fragility fractures. These criteria 
have since been accepted and extensively used.  
Although osteoporotic fracture may occur at various skeletal sites, the most 
common sites include the hip, spine, and wrist (65). In the United States, 44 million 
women and men are at risk for osteoporosis with 55% of these individuals being over the 
age of 50. It is estimated that the prevalence of this disease in women over the age of 50 
will increase to 41 million in 2020, whereas the incidence in men is likely to reach over 
17 million (65). Currently, greater than 1.5 million osteoporosis-related fractures occur 
each year. Among the individuals that experience these fractures, it is estimated that 
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500,000 will be hospitalized, 800,000 will visit an emergency room, 2.6 million will see a 
physician, and 180,000 will be placed in a nursing home (66). The increased incidence of 
osteoporosis-related fractures has become a burden to the healthcare system. In 2005, it 
was estimated that the incidence of fracture was more than 2 million at a total cost of $19 
billion. In 2006, the direct healthcare costs associated with osteoporosis ranged from 12 
to 18 billion dollars (66). By 2025, it is predicted that fractures will increase to more than 
3 million per year and the annual projected fracture costs will be $25.3 billion (67). The 
lifetime risk of osteoporotic fracture in the Western world is 40-50% chance in women 
and 13-22% in men (68).  
Factors that contribute to the risk of osteoporosis include, but are not limited to, 
low-peak bone mass, low dietary intake of calcium and vitamin D, hormonal factors (e.g. 
abnormality of PTH secretion), tobacco smoking, physical inactivity, race, small body 
frame size, and a personal or family history of fracture (65,69). Recently, increasing 
evidence has demonstrated that chronic inflammatory conditions such as periodontitis 
and RA are also associated with osteoporosis (70,71). Studies have shown that vitamin D 
status is a very important dietary factor associated with bone health in young and old 
females and males as well as in various ethnic groups. For instance, adolescent girls with 
high vitamin D status (≥ 74.1 nmol/L) were shown to have higher BMD, lower bone 
turnover markers, and lower parathyroid hormone (PTH) levels compared to those with 
lower vitamin D status (72). A double-blind, randomized, controlled trial, demonstrated 
that calcium supplementations combined with vitamin D positively affected BMD and 
BMC in peri- and post-menopausal women (73). In a cohort study of elderly men, serum 
25-hydroxyvitamin D3 (25-(OH)D3) of elderly men was found to be a determinant of 
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BMC, cortical thickness, and biomechanical parameters of the femoral neck (74). 
Furthermore, young men, 25-(OH)D3 were also found to be a significant determinant of 
BMC and BMD (74). Serum 25-(OH)D3 was also found to be positively associated with 
bone health in older, community-dwelling men (75), and in white men (76). In non-
Hispanic white adults over the age of 65, serum 25-(OH)D3 was inversely related to hip 
fracture risk (77). Beneficial effects of vitamin D on bone health have also been 
demonstrated in women in the United Kingdom (U.K.), South Asia, and United Arab 
Emirates (UAE). South Asian women of Pakistani Muslim origin living in the U.K. with 
serum 25-(OH)D3 insufficiency/deficiency were found to have reduced bone mass at the 
hip and wrist (78), while vitamin D deficiencies in women living in UAE were found to 
be associated with increased bone turnover (79). Hence, it is evident that vitamin D is an 
important nutrient for maintaining skeletal health in a variety of populations. 
 
Vitamin D Status 
Currently, 25-(OH)D3 and 1,25-dihydroxyvitamin D (1,25(OH)2D3), two vitamin 
D metabolites, are used as indicators of vitamin D status. Serum 25-(OH)D3 is the 
vitamin D metabolite most frequently used to assess vitamin D status because it 
corresponds to cutaneous production and food intake of vitamin D (80). Moreover, serum 
25-(OH)D3 has a longer half-life (10.4 days) (81) compared to 1,25(OH)2D3 with a half-
life of 4-6 hours (82). Although circulating 1,25(OH)2D3 has not been considered a part 
of the routine vitamin D status clinical assessment, it has been suggested that in the future 
evaluation of 1,25(OH)2D3 may have merit (83).  
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Individuals at greatest risk of vitamin D insufficiency and deficiency include the 
elderly, hospitalized patients, and young adults with minimal exposure to sunlight or 
limited vitamin D intake (24). Vitamin D status among the elderly is recognized as one of 
the most significant public health concerns because the synthesis of vitamin D in the skin 
decreases with age and the renal conversion of 25-(OH) D3 to 1,25(OH)2D3 is less 
efficient resulting in compromised vitamin D status (23,84). 
Vitamin D status varies among the elderly populations from the United States and 
Europe (Scandinavia, Central, and Western Europe) (37). Even among both community-
dwelling and institutionalized elderly populations in the U.S. and Europe, serum  
25-(OH)D3 levels are different. Comparing serum 25-(OH)D3 in community-dwelling 
with institutionalized elderly population enable researchers to determine whether 
different duration of sun exposure would affect vitamin D synthesis in these populations. 
Community-dwelling elderly populations from the U.S. have an average serum 25-
(OH)D3 of 71-86 nmol/L, whereas 25-(OH)D3 in a similar group of Europeans is 21-55 
nmol/L. In the U.S., the institutionalized elderly have serum 25-(OH)D3 levels of 53-45 
nmol/L compared to 9-37 nmol/L for those from Europe. Lips and colleagues (37) 
reported that patients with hip fracture in the U.S. had serum 25-(OH)D3 levels of 
approximately 32 nmol/L, whereas those in Europe were 19-46 nmol/L. Generally, the 
minimum level of serum 25-(OH)D3 for fracture prevention ranges between 50-80 
nmol/L.  
There continues to be some controversy related to definition of insufficient, 
deficient, optimal, and toxic vitamin D status (Table 1). For fracture prevention, the 
recommended serum 25-(OH)D3 concentrations ranged from 50-80 nmol/L, but some 
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researchers recommended 70-80 nmol/L (11). Alternatively, BMD can be used to 
estimate optimal vitamin D levels. 25-(OH)D3 levels approximately 94 nmol/L was 
shown to be the preferred level for maintaining total hip BMD in young and older 
populations in the U.S. (49). Although the optimum level varies, experts recognize that 
the intake of at least 20-25 µg (800-1000 international unit, IU)/day of vitamin D is 
necessary for older men and women to reach serum 25-(OH)D3 of 75 nmol/L for fracture 
prevention (11). For optimal health benefits, both children and adults should maintain > 
75 nmol/L of 25-(OH)D3 (85).  
Table 1. General Classification of Vitamin D Status 
Classification                Serum 25-(OH)D3  (nmol/L) 
Insufficiency                40-80  (12) 
              25-50  (13) 
              51-74  (87) 
Deficiency                <30  (12) 
              0-25  (13) 
Optimum level                90-120  (12) 
              70-250  (13) 
               >75  (11, 32) 
Toxicity                 >250  (13) 
               >375  (87) 
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Circulating 25-(OH)D3 >375 nmol/L is defined as vitamin D intoxication (85). 
Vitamin D intoxication is characterized by elevated plasma vitamin D concentration that 
may result in hypercalcemia (85,86). In addition, high amounts (i.e., ≥ 600 nM ) of “free” 
1,25(OH)2D3 displaced from vitamin D-binding protein (DBP), such as in the case of 
patients with vitamin D toxicity may also cause hypercalcemia (87,88). Hypercalcemia 
may present with symptoms mimicking acute myocardial infarction such as fatigue, 
anorexia, and chest pain (89). Both the physicians and the manufacturers should be 
certain that vitamin D supplementation prescribed and manufactured are at the 
appropriate levels to prevent vitamin D intoxication (90).  
 
Sources of Vitamin D  
The recommended daily intake assumed to be adequate, (i.e., adequate intake or 
AI), in 50-70 years old is 10 µg (400 IU)/day; the AI for adults over the age of 70 is 15 
µg (600 IU)/day. The tolerable upper intake level (UL) for vitamin D among adults in the 
U.S. is 50 µg (2000 IU)/day. It should be noted that sunlight exposure can provide an 
adult up to 250 µg (10,000 IU)/day of vitamin D, which exceeds the UL. However, 
excessive sun exposure does not result in vitamin D intoxication because previtamin D3 
and vitamin D3 can be photolyzed or photodegraded to noncalcemic products (e.g. 5,6-
transvitamin D3, suprasterol I, and suprasterol II ) which are biologically inactive (91,92). 
It is not known whether these products have any biological significance, however, 5,6-
transvitamin D3 analog had been shown to stimulate intestinal calcium transport and 
modestly stimulate mobilization of calcium from the bone of anephric rats (93). Sun 
exposure is the major source of vitamin D, however, vitamin D (i.e., D2 and D3, 
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ergocalciferol and choleclaciferol respectively) can also be obtained from foods (5). 
Vitamin D2 is synthesized from ergosterol, a provitamin, to vitamin D2, and is derived 
from the irradiation of plant sterols and converted to ergocalciferol when exposed to 
ultraviolet (UVB) radiation (5). Although there are limited foods that contain vitamin D 
(i.e., D2 and D3), some of the best dietary sources of vitamin D3 (cholecalciferol) include 
fish (e.g. salmon, mackerel, and sardines), fish liver oils, egg yolk, and liver (86). Some 
wild mushrooms contain D2 and meat contains small amounts of D3. Most of the 
naturally occurring vitamin D-rich foods are not consumed on a regular basis, therefore, 
Americans depend on vitamin D-fortified foods such as breakfast cereals, milk, 
margarine, and orange juice to meet their daily vitamin D requirements (61,94). 
Generally, vitamin D status in the U.S. is better compared to Europe (95), Canada, 
Australia, and New Zealand because of the availability of fortified foods (96). Although 
vitamin D-fortified foods provide the greater part of dietary intake in the U.S., vitamin D 
deficiency has been attributed to low fortification level in foods (5), insufficient intake of 
these foods, reduced consumption of milk and dairy products (97). Even though dietary 
sources of vitamin D have been recognized, their (vitamin D2 and D3) content in foods 
have not been developed. Hence, the Nutrient Data Laboratory (NDL) at the Beltsville 
Human Nutrition Research Center, Agricultural Research Service, United States 
Department of Agriculture has recently begun to collaborate with vitamin D experts to 
analyze vitamin D content of food samples and to develop acceptable values for vitamin 
D2 and D3. The outcome of this work will be used in the National Nutrient Database as 
Standard Reference for acceptable values (98).  
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Other Factors Influencing Vitamin D Status 
Diet is recognized as an important factor for vitamin D status, but environmental 
and personal factors may also play a role. For example, latitude, season, time of day, the 
amount of ozone and cloud, aerosol, and albedo (i.e., reflectivity of a surface) are among 
the environmental factors that affect vitamin D status. Skin type, age, clothing, and the 
use of sunscreen are some of the personal factors that affect the synthesis of vitamin D 
and hence affect vitamin D status. In addition to that, premature birth, malabsorption, and 
obesity also contribute to the alteration in vitamin D status (99). 
  
Vitamin D Metabolism 
Sunlight is the primary source of vitamin D for humans (3,4). As skin is exposed 
to ultraviolet radiation, 7-dehydrocholesterol (7-DHC) found in the epidermal layer of the 
skin is converted to previtamin D3. A thermal reaction further converts previtamin D3 to 
vitamin D3 at the epidermal layer. Vitamin D3 then enters the circulation and is 
transported by a high-affinity binding protein, vitamin D binding protein (DBP), to fat for 
storage, or to the liver where it is further metabolized. In the hepatocytes (100), vitamin 
D-25-hydroxylase (25-OHase) metabolizes vitamin D3 to 25-(OH)D3 by adding a 
hydroxyl group on carbon 25 (101). CYP27A1 is the gene encoding 25-OHase, which is 
expressed primarily in the liver but also in the kidney and other tissues (100). CYP27A1 
is a multifunctional cytochrome P450 enzyme found in the mitochondria for catabolism 
and removal of cholesterol from cells (102) as well as the synthesis of vitamin D3 (103-
106). Due to its functions on cholesterol-27-hydroxylation and 25-hydroxylation of 
vitamin D3, CYP27A1 also known as sterol 27-hydroxylase, P450c27 and mitochondrial 
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vitamin D3 25-hydroxylase (103-107). As indicated previously, 25-(OH)D3 is used as an 
indicator of vitamin D status as it leaves the liver, re-enters the circulation, and is 
transported to the kidney for further hydroxylation (6). 
In the kidney, 25-(OH)D3 is converted to 1,25(OH)2D3 in cells within the kidney 
by 25-hydroxyvitamin D3-1α-hydroxylase (1α-OHase) present mainly in the proximal 
convoluted tubule (3,6,29,108). Cytochrome P450, family 27, subfamily b, polypeptide 1 
(CYP27B1) is the gene responsible for the 25-hydroxylation of 25-(OH)D3 to 
1,25(OH)2D3 (109). It is not only expressed in the kidney, but is also expressed in bone 
(110), macrophages (111), intestine (colon), pancreas (islets), and placenta (112). 
1,25(OH)2D3 re-enters the circulation and is transported via vitamin D binding proteins 
(DBP) to the target tissues, such as bone, intestine, heart, pancreas, and immune cells 
(e.g. T- and B-lymphocytes) that expresses VDR (4,6,46). Regulation of vitamin D 
homeostasis also requires 25-hydroxyvitamin D-24-hydroxylase (24,25(OH)2D3). 
CYP24A1, the cytochrome P450, family 24, subfamily A, polypeptide 1, is a gene 
encoding the enzyme 24,25(OH)2D3 in the kidney that is involved in the catabolism of 
1,25(OH)2D3 and 25-(OH)D3 when 1,25(OH)2D3 is sufficiently available (113). 
CYP27B1 and CYP24A1 are vital genes encoding vitamin D enzymes that tightly 
regulate the production of vitamin D hormone in the body (114). By studying these 
genes, we are able to get a better understanding on vitamin D regulation in the cellular 
level.  
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Vitamin D Receptor (VDR) and Functions 
VDR is a member of the steroid nuclear hormone receptor superfamily involved 
in the regulation of gene expression (115). While VDR was traditionally recognized for 
its expression on tissues such as bone, small intestine, heart, and pancreas, it is now 
known to be expressed on a variety of cells including T- and B-lymphocytes and 
monocytes (4,29,46). 1,25-(OH)2D3 binds to the cytoplasmic VDR in target tissues 
causes the rejection of corepressors (e.g. nuclear receptor corepressor) (116). It then 
translocates to the nucleus and heterodimerizes with retinoid-X receptor (RXR), a 
member of the superfamily of nuclear hormone receptors which is activated by the 
vitamin A metabolite  9-cis-retinoic acid (9-cis RA) (116-118). The binding increases the 
affinity of the VDR/RXR heterodimeric complex for the vitamin D response element 
(VDRE), which is a specific sequence of nucleotides in the promoter region of vitamin D 
target genes (119). The binding of VDR/RXR heterodimeric complex to VDRE in the 
promoter region induces transcriptional activation or suppression (120). VDRE can be 
found thousands of basepairs distal from the transcription initiation site; coactivators 
have been associated with the bending of DNA following their binding to VDR/RXR. 
However, it is unclear whether coactivators are essential to connect VDR/RXR 
heterodimeric complex to its VDRE (121). To date, the two coactivator complexes that 
have been identified are the steroid receptor activator complex (SRC), consisting of p160 
family of SRC1, 2 and 3 coactivators, and the vitamin D receptor interacting protein 
complex (DRIP) (122,123). These coactivators bind to specific domain of the VDR for 
transcription activation. 
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In order to understand transcriptional activation, one must be familiar with the 
structure of VDR (Figure 1). VDR is composed of: 1) an A/B region that contains the 
ligand-independent AF-1 transactivation domain; 2) a C region containing the DNA-
binding domain; 3) a D region that includes the linker domain; and 4) an E region 
containing the ligand-binding domain, the dimerization surface and the ligand-dependent 
AF-2 transactivation domain (124). The SRC coactivator interacts with AF-2 
transactivation domain and recruits histone acetyltransferases (HATs) and 
methyltransferases (MeTs) to the VDR forming a multisubunit complex interacting with 
VDRE, destabilizing the interaction of DNA and the histone core, facilitating 
transcription (123,125). Similarly, DRIP coactivator interacts with AF-2 transactivation 
domain and recruits RNA polymerase II to the transcription initiation site (125).  
 
Figure 1. The Structural Organization of VDR 
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Vitamin D’s Classical Role in Calcium Homeostasis 
The traditional role of vitamin D is to optimize the absorption of calcium and 
phosphorous from the intestinal lumen and increase the reabsorption of calcium from the 
kidneys. Vitamin D promotes the formation and mineralization of bone and is essential 
for the maintenance of mineralized skeleton (4). Calcium is transported by a vitamin D-
dependent transcellular pathway, which is highly expressed in the proximal intestine 
(126). The process begins with luminal calcium entering duodenal enterocytes through a 
calcium channel, transient receptor potential cation channel, subfamily V, member 6 
(TRPV6) located on the apical membrane of the enterocyte surface (127). Calcium is 
transported by calbindin 9k, a cytosolic calcium transport protein, from the apical 
membrane to the basolateral membrane, where vitamin D-dependent plasma membrane 
Ca(2+)-ATPase (PMCA1) pump is located (126,127). The regulation of intestinal and 
renal calbindin 9K is highly dependent on VDR and was suggested to be an important 
mediator for calcium reabsorption in the kidney (128). The transcription of calbindin 9k 
and TRPV6 are enhanced by the binding of vitamin D to VDR (129).  
The small intestine, kidney, bone, and parathyroid glands are the tissues most 
involved in the maintenance of systemic calcium homeostasis. Vitamin D functions 
together with the peptide hormone, PTH, which regulates serum calcium and inorganic 
phosphate levels through its effects on the kidney and bone (130,131). The relationship of 
25-(OH)D3 to PTH is characterized as inverse relationship in that when 25-(OH)D3 is 
adequate, PTH is suppressed (35,36). In contrast, low serum 25-(OH)D3 in response to 
elevated PTH promotes calcium resorption from the skeleton, enhances bone loss, and 
increases the risk of fracture (37).  
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Studies have shown that vitamin D plays a crucial role in skeletal health. 
Traditionally, vitamin D deficiency has been recognized as a cause of severe bone 
deformities or rickets in children (132). Rickets in children or osteomalcia in adults is a 
metabolic bone disease caused by a defect in phosphate and/or vitamin D metabolism 
(133). In osteomalacia, the amount of osteoid or the organic matrix of bone, is in excess 
to adequate bone mineralization. These children manifest defective mineralization of 
bone and the cartilaginous matrix of the growth plate. Impaired bone mineralization in 
osteomalacia may lead to osteoporosis, which then predisposes an individual to fractures 
(133). In postmenopausal women, vitamin D deficiency has been reported in association 
with acute hip fracture (39). Irish postmenopausal women were shown to have low 
vitamin D status (< 50 nmol/L), but not vitamin D deficiency during late wintertime 
(134). Low serum concentration of 25-(OH)D3 (≤ 12 ng/mL) was associated with 
increased risk of osteoporotic fracture in persons aged 65-75 years in the Netherlands 
(135) and may be associated with lower forearm BMD in young Japanese women (136). 
Various clinical studies have been conducted to further examine the relation of vitamin D 
and skeletal health. Clinical studies in the elderly have shown that bone loss is prevented 
and bone density is improved when supplemented with 400-800 IU/day of vitamin D, 
given alone or in combination with calcium. Furthermore, osteoporotic fractures in the 
elderly were prevented with daily supplementation of 400-800 IU of vitamin D and 700-
800 mg of calcium (137). Vitamin D supplementation with added calcium improves bone 
mineral density and reduces markers of bone turnover in both young and old populations 
(31,138).  
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Studies involving animal models have been used to examine the role of vitamin D 
in bone metabolism. For instance, the role of vitamin D receptor (VDR) was examined in 
VDR gene knockout (KO) mice (139,140). Before weaning, the VDR KO mice did not 
exhibit defects in development and growth, however, after weaning, VDR KO mice did 
show defects in development and growth, resulting resistance to 1,25(OH)2D3 action 
(139,140). The growth plate of the femur from 1α-OHase-ablated (CYP27B1) mice were 
expended with disorganized cartilage layers, demonstrating that 1α-OHase is an essential 
enzyme for bone metabolism (141). Dardenne and colleagues (141) further investigated 
the effect of 1,25(OH)2D3 administration on the 1α-OHase-ablated mice and showed that 
1,25(OH)2D3 was effective in restoring biomechanical properties of bone tissue and 
reducing pseudo-vitamin D deficiency rickets (PDDR). Vitamin D was shown to prevent 
binge alcohol-induced bone loss in Sprague-Dawley rats and the 1,25(OH)2D3/VDR 
system is required for optimal osteoclastic bone resorption and osteoblastic bone 
formation (142-144). Based on animal studies, both VDR and CYP27B1 involved in 
vitamin D metabolism are critical for bone metabolism and the maintenance of skeletal 
health. 
 
Inflammation 
Inflammation is a defense reaction occurring in the body in response to infection 
(145) and tissue damage (146) and may be characterized as either acute or chronic (147). 
The major characteristics of the inflammatory response includes vasodilation to increase 
blood flow to the site of infection; increased vascular permeability to allow soluble 
mediators to diffuse across the endothelial barrier and to enter the site of infection; and 
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accumulation of immune cells (e.g. monocytes/macrophages, T- and B-lymphocytes, and 
granulocytes) at the infected area to reduce tissue damage (148). Once monocytes enter 
the site of infection, they may differentiate into macrophages with phagocytic activity. 
Chemical mediators such as lymphokines (i.e., cytokines secreted by activated 
lymphocytes) are required for the activation of macrophages which serve to either 
promote or suppress inflammation depending on their phenotype (149). 
T-lymphocytes, type I T helper (Th1) and type II T helper (Th2) cells are subsets 
of T-lymphocytes that produce interferon (IFN)-γ, interleukin (IL)-2, tumor necrosis 
factor (TNF)-β and IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 respectively (150). Cytokines 
produced by both Th1 and Th2 cells demonstrate phagocyte-dependent protective 
capabilities, with Th1 cytokines responsible for macrophages activation and cell-
mediated immunity, while Th2 cytokines responsible for antibody production, eosinophil 
activation, and macrophage functions inhibition (151). Pro-inflammatory cytokines 
produced by Th1 cells and anti-inflammatory cytokines produced by Th2 cells are the 
two major groups of cytokines involved in inflammation (152).  
 
Bone Metabolism in Normal Conditions 
In order to understand the response of bone to inflammation, one must first have a 
basic understanding of bone metabolism under normal conditions. In the adult skeleton, 
bone is constantly remodeled by a process known as resorption by osteoclasts followed 
by bone formation by osteoblasts (153). Under normal condition, osteoclast breakdown 
or resorb bone, forming dish-shaped cavities known as lacunae. Osteoblasts will then 
deposit new bone (i.e., osteoid) at the site of the lacunae until it is fully replaced with new 
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bone (153). In addition, the process of bone resorption and formation is tightly regulated 
by receptor activator of nuclear factor kappa B/ receptor activator of nuclear factor kappa 
B ligand/osteoprotegerin (i.e., RANK/RANKL/OPG) system (153). The ligand for 
receptor activator for NF-κB (RANKL) is expressed by osteoblasts and activated T-
lymphocytes and binds to its receptor RANK which is expressed on osteoclast precursors 
and dendritic cells (154). The binding of RANKL to RANK allows osteoclast to 
differentiate and to become mature bone resorpting cells (154). Osteoprotegerin (OPG), 
serves as a soluble decoy receptor of RANKL, and can inhibit RANK-RANKL 
interaction (155,156). When RANK-RANKL interaction occurs and mature osteoclasts 
are formed, they attach to the bone surface forming a ruffled border enclosure so that 
hydrogen ions and proteolytic enzymes can be released within a confined environment. 
These two events in turn lead to the activation of tartrate-resistant acid phosphatase 
(TRAP) and cathepsin K (CATK), thus initiating bone resorption (157).  
 
Bone Metabolism in Inflammatory Conditions 
Inflammation can cause an imbalance in normal bone remodeling usually in favor 
of bone resorption exceeding new bone formation (158). Such alterations in bone 
metabolism result in bone loss (i.e., osteopenia) or osteoporosis and further complicate 
many chronic inflammatory conditions such as rheumatoid arthritis, periodontitis, certain 
cancers and HIV. Clinical studies have demonstrated that patients with rheumatoid 
arthritis (RA), an inflammatory joint disease, exhibit a significant decrease in BMD 
including lumbar spine and femur BMD (159,160). These changes in BMD coincided 
with elevated pro-inflammatory cytokines, in particular IL-1β, IL-6, and TNF-α, in the 
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inflamed synovium and synovial fluid of these patients (161,162). More recently, the pro-
inflammatory cytokine IL-17, which is produced predominantly by T-lymphocytes, was 
also found to be associated with RA (163). Further investigation into the effects of 
inflammation on bone in RA patients, have shown that urinary and serum markers of 
bone resorption (i.e., pyridinoline, deoxypyridinoline, N-telopeptides and C- telopeptides 
of type I collagen) were significantly increased in these patients (164,165). The serum 
bone formation marker, procollagen type I C-terminal telopeptide (ICTP) was elevated in 
RA patients, but not procollagen type I C-terminal propeptide (PICP) or procollagen 
Type I N-terminal propeptide (PINP) (166). These findings confirmed that in RA, bone 
resorption is accelerated and bone formation is decreased or remain unchanged. 
Another chronic inflammatory disease, periodontitis has also been associated with 
bone or tooth loss (167). Femur BMD was found to be positively correlated with 
interproximal (i.e., between the adjoining surface) alveolar bone loss (168). Patients with 
inflamed gingival tissue tend to have increased circulating levels of pro-inflammatory 
cytokines including IL-1β, IL-6, and TNF-α (169-171). These cytokines in addition to 
cyclooxygenase (COX)-2 tend to be highly expressed in patients with inflamed gingival 
tissue (170,172,173). Therefore, gingival inflammation is likely to serve as a source of 
pro-inflammatory mediators that produce local as well as systemic effects on skeletal 
tissue.  
In terms of bone loss in other chronic inflammatory conditions such as HIV and 
breast cancer, decreased in BMD is common (174,175). Patients with HIV have been 
shown to have decreased BMD of the hip, lumbar spine, proximal femur, and total body 
(176,177). Biochemical markers of bone metabolism suggest that these alterations in 
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bone density result from increases in bone resorption and decreases in bone formation 
(178,179). Additionally, decreased BMD is often reported with cancers of the breast and 
lung that is associated with osteolytic metastatic bone disease (180-182). Other examples 
exist in the literature of patient populations who suffer from osteoporosis associated with 
chronic inflammatory diseases or conditions including, atherosclerosis (183), pancreatitis 
(184), inflammatory bowel disease (IBD) (185), and lupus (186). 
 
Animal Models of Chronic Inflammation and Bone Loss 
Animal models have provided a great deal of insight into the relationship between 
chronic inflammation and bone. For instance, a rat model of periodontitis-induced bone 
loss showed a significant increase in alveolar bone resorption (187). Pro-inflammatory 
cytokines involved in bone loss such as TNF-α, IL-1β, IL-6 (188,189), and IL-17 (190) 
have been reported in animal arthritis models. RANKL was significantly elevated in the 
joints (local) and serum (systemic) of arthritic rats, however, local and systemic bone loss 
were prevented when RANKL was inhibited by OPG (191). RANKL knockout mice 
showed a significant decrease in bone resorption compared to the control, confirming that 
RANKL is an essential factor for osteoclast differentiation in bone erosion associated 
with arthritis (192). In vivo, elevated numbers of osteoclasts were reported in 
subchrondral bone, which is situated beneath cartilage and is the common erosion site 
near synovial inflammatory tissue. Osteoblasts were found primarily along the cortical 
surface, a more distant site, confirming that bone resorption activity is higher than bone 
formation activity at inflammatory sites. Furthermore, the authors also demonstrated that 
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blockade of TNF-α decreased osteoclast numbers and enhanced osteoblast numbers, 
favoring bone formation (193). 
LPS is the major constituent of the cell wall of Gram-negative bacteria such as E. 
coli 0157:H7 and Salmonella (194), whose function is to maintain the membrane 
structure. LPS induces an immune response, and to be highly immunogenic. The 
immunogenic response of LPS begins when LPS in the circulation binds to the liver-
derived lipopolysaccharide binding protein (LBP), an acute phase protein (195). This 
LPS-LBP complex interacts with the co-receptor cluster of differentiation (CD14) present 
on the surface of monocytes/macrophages, subsequently facilitating its interaction with 
the plasma membrane protein toll like receptor 4 (TLR4) (195). The activated TLR4 
recruits the adaptor protein myeloid differentiation factor (MyD88), which in turn recruits 
IL-1 receptor associated kinases 1 (IRAK1) and IRAK4 (196,197). Upon recruitment or 
binding of IRAK4 to the receptor complex, the IRAK1 is phosphorylated, which in turn 
facilitates the interaction of TNF receptor-associated factor 6 (TRAF6) (198,199). When 
the IRAK1-IRAK4-TRAF6 complex dissociates from TLR4, TLR4 activates downstream 
kinases such as transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1), 
TAK1-binding protein 1 and 2 (TAB1 and TAB2) (200). This eventually activates 
mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) pathways and 
thereby regulates gene expression (201). Due to the efficacy of LPS in creating 
downstream inflammatory signaling pathways, it has been used to initiate immune 
response in animals, human, and cell culture studies (47,202,203). 
A model of low-grade chronic inflammation was developed in our laboratory to 
study the influence of subclinical inflammation on bone loss (47). In this study, the 
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continuous inflammatory response in the animals was confirmed by elevation in 
neutrophils and monocytes throughout the 90-day study period and up-regulation of pro-
inflammatory such as TNF-α, IL-1β, and COX-2 in the bone at the end of the study. This 
model of inflammation in Sprague-Dawley male rats was shown to produce a decrease in 
BMD and trabecular bone microarchitecture at 3 months of age (47). The bone loss 
occurred in conjunction with increases in TNF-α, IL-1β and COX-2 protein expression in 
the bone. Moreover, in C57BL/6J mice this model was shown to produce significant bone 
loss in 30 days, which appeared to be mediated by up-regulating TNF-α (48). Hence, it 
appears that TNF-α plays a significant role in bone response to chronic inflammation in 
this model. Therefore, we propose to use the chronic LPS model of low-grade chronic 
inflammation to study the effects of inflammation on systemic and local vitamin D 
metabolites in mice. Additionally, we will study the potential role of TNF-α in mediating 
these effects.  
 
The Discovery of Vitamin D’s Relation to Inflammation 
 In addition to the role of vitamin D in calcium homeostasis, vitamin D also plays 
an important role in the immune system. Two of the early events that led to this discovery 
of this relationship were the observation that several immune cells (e.g. T-lymphocytes, 
monocytes and macrophages) expressed VDR (4,42,47) and that vitamin D was shown to 
modulate macrophage and lymphocyte functions associated with tuberculosis (TB) (204). 
The stage of maturation of monocytes and macrophages determine the levels of 
production of 1,25(OH)2D3 and the expression of VDR. An in vitro study utilizing 
peripheral mononuclear cells (PMC) showed that the capacity to synthesize 1,25(OH)2D3, 
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but not 24,25(OH)2D3 and to express VDR, is enhanced when blood monocytes 
differentiated into macrophages. This indicates the importance of the maturation stage of 
monocytes and macrophages in 1,25(OH)2D3 production (43). In 2000, Veldman and 
colleagues reported that VDR was highly expressed in T-lymphocytes, but not B-
lymphocytes, and suggested that vitamin D directly regulates T-lymphocyte function 
(205). For some time it has been known that the prevalence of new cases of TB increased 
during the colder seasons when limited sun exposure, resulting in limited cutaneous 
synthesis of vitamin D, and low serum levels of vitamin D were reported. Originally, 
exposure to UV light successfully cured tubercular infection in tuberculosis patients 
before the availability of drugs. However, it was unclear whether vitamin D was actually 
involved with immune function or whether these effects were mediated by other 
mechanisms. 
  In the 1980s, patients with tuberculosis were shown to have low serum 
concentration 25-(OH)D3 compared to the healthy controls (206). Studies were conducted 
to determine the potential relationship between vitamin D and tuberculosis. Using in vitro 
studies, 1,25(OH)2D3 was shown to effectively modulate the cytokine response to 
tuberculosis antigens (207). Incubation of human monocytes in 1,25(OH)2D3 at a 
concentration of 10-9 mol/L resulted in anti-tuberculosis activity (204). Exposure of 
mature macrophages to 1,25(OH)2D3 at 4 µg/ml (1040 nmol/L) was able to activate 
macrophages to express tuberculo-immunity, where the activated macrophages are able 
to kill intracellular tubercle bacilli (208). Another study showed that 1,25(OH)2D3 
metabolism leads to activation of macrophages and suppresses the intracellular growth of  
TB, indicating that vitamin D can modulate macrophage function (209). A more recent 
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study showed that vitamin D’s anti-microbial activity against tuberculosis is dependent 
on cathelicidin induction (210). Cathelicidins are antimicrobial peptides of the innate 
immune system that have an anti-inflammatory role by down-regulating inflammation via 
inhibition of TLR4 signaling (211). As mentioned previously, vitamin D was used to treat 
TB in sanatoriums before the antibiotics came in to use, however, the relationship of 
vitamin D and the treatments of TB remain unclear. Later, vitamin D was shown to 
modulate macrophage and lymphocyte associated with TB. Since macrophage and 
lymphocyte are involved in inflammatory response, thus vitamin D is considered to play 
a role in inflammation.  
 
Vitamin D and Inflammatory Conditions  
The relationship of vitamin D and inflammation has been shown clinically. For 
example, patients with inflammatory bowel disease (IBD) were found to have low BMD, 
in the lumbar spine, total hip, and total body in accordance to low serum 25-(OH)D3 
concentrations (49-52). Suppressed vitamin D level has also been reported in diabetes, 
which is considered to have an inflammatory component (53,54). Epidemiological studies 
indicate that patients with type 1 diabetes mellitus have lower serum concentrations of 
25-(OH)D3 and 1,25(OH)2D3 than controls (212,213). Vitamin D insufficiency is 
considered a risk factor for diabetes, particularly type 2 (13). Furthermore, peripheral 
blood monocytes from type 2 diabetics were shown to have a pro-inflammatory profile 
(i.e., elevated TNF-α, IL-6, IL-1, IL-8, COX-2, intercellular adhesion molecule (ICAM)-
1 and B7-1 or CD80 molecule) and the expression of several of these cytokines (i.e., 
TNF-α, IL-6, IL-1, IL-8) were down-regulated with the addition of 1,25(OH)2D3 (57). 
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Suzuki and colleagues (214) showed that type 2 diabetics have low serum 25-(OH)D3. 
These studies showed that diabetic patients not only demonstrate inflammatory 
conditions but also display low vitamin D.  
  Patients with RA were found to have low serum concentration of 25-(OH)D3 (55). 
A clinical study conducted on male and female patients with RA between the ages of 18-
80 years showed that high disease activity in these patients is negatively correlated with 
serum levels of 1,25(OH)2D3 (56). Research showed that, aging decreases the activity of 
the kidney to produce 1,25(OH)2D3 from 25-(OH)D3 (23,84), however, the authors found 
only week negative correlation between age and serum 1,25(OH)2D3  in this patient 
population, indicating disease activity may be affecting 1,25(OH)2D3 (56). A study 
comparing Northern (Estonia) and Southern (Italy) European RA patients showed that 
serum concentrations of 25-(OH)D3 in female RA patients from Northern (Estonia) 
Europe were negatively correlated with RA disease activity score (215). A subsequent 
study demonstrated that oral treatment with 2 µg/day of 1,25(OH)2D3 lowered the risk of 
RA (216).  
The relationship between inflammation and vitamin D has been explored by using 
animal models. In an experimental murine model of colitis, VDR knockout (KO) mice 
were shown to have severe IBD symptoms (217). Cantorna and colleagues (218) utilized 
IL-10 KO mice, which exhibit IBD symptoms, to study the effects of 1,25(OH)2D3 on 
IBD. The mice were made vitamin D deficient, vitamin D sufficient or supplemented 
with 1,25(OH)2D3 and the severity of IBD development was examined. The authors 
showed that vitamin D deficiency aggravates symptoms of IBD as indicated by severe 
diarrhea and weight loss. No severe diarrhea or weight loss were shown in vitamin D 
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sufficiency, however, vitamin D supplementation ameliorated symptoms of IBD in the 
IL-10 KO mice (218). The beneficial effects of vitamin D was further analyzed in a 
multiple sclerosis (MS) mouse model, where 1,25(OH)2D3 was found to reverse 
experimental autoimmune encephalomyelitis (EAE) by inhibiting chemokines (219), 
iNOS, and monocyte recruitment into the CNS (220). Furthermore, treatment with 
1,25(OH)2D3 was shown to prevent acute liver rejection following transplantation in both 
Sprague-Dawley and Wistar rats by inhibiting IFN-γ expression and increasing IL-10 
expression. These data indicate that 1,25(OH)2D3 induces secretion of cytokines from 
Th2, which has to anti-inflammatory role, protect liver function and alleviate liver 
rejection (221). 
  In vitro studies have also provided insight into the relationship between vitamin D 
and immune function. Immune stimuli such as LPS and IFN-γ have been shown to 
regulate macrophages 1-α hydroxylase (CYP27B1) expression, the enzyme that converts 
25-(OH)D3 to 1,25(OH)2D3 (222). Furthermore, LPS can attenuate 1,25(OH)2D3/VDR 
functions and may affect the ability of 1,25(OH)2D3 to induce myloid differentiation into 
monocytes/macrophages (223). Liu and colleagues (224) demonstrated that activation of 
toll-like receptors (TLR) TLR2/1, in human monocytes and macrophages up-regulated 
the expression of VDR and CYP27B1 genes inducing the antimicrobial peptide 
cathelicidin to kill intracellular mycobacterium tuberculosis. The activated VDR results in 
up-regulation of cathelicidin antimicrobial peptide (CAMP), which has direct 
antimicrobial effects on tuberculosis. Further analysis of human monocytes cultured in 
serum containing media, in the presence and absence of 25-(OH)D3 demonstrated that 
25-(OH)D3 is required for cathelicidin expression. This study demonstrated there is a 
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strong link between vitamin D, TLR, and antimicrobial responses of cathelicidin in 
immune response (224).  
 
Vitamin D, Bone, and Inflammation  
  Most of the immune cells, in particular antigen-presenting cells (macrophages and 
dendritic cells) and activated T-lymphocytes, express VDR (225,226) in addition to 
express 1α-OHase (222,227) and 24OHase (228). The 1α-OHase found in these immune 
cells is identical to those found in the kidney and is essential for the hydroxylation of 25-
(OH)D3  to 1,25(OH)2D3 (222,227). Renal 1α-OHase is regulated by PTH and 
1,25(OH)2D3 itself, whereas the immune cells 1α-OHase is controlled by immune signals, 
with IFN-γ and Toll-like receptor (TLR) agonists being powerful stimulators (222). The 
classical actions of vitamin D to maintain calcium and phosphate homeostasis and bone 
mineralization (4), is in contrast to the nonclassical actions of vitamin D affecting the 
immune system and cellular differentiation (229). Vitamin D deficiency or insufficiency 
is associated with increased risk of chronic inflammatory conditions such as TB and 
leprosy (230-232), which may be caused by the decrease in monocyte activation and 
differentiation into macrophages induced by activated vitamin D (43). Various factors 
including vitamin D stimulate the transcription and production of RANKL, indicating 
that vitamin D has significant effects on the RANK/RANKL/OPG system in regulating 
bone metabolism. In terms of the relationship between vitamin D and 
RANK/RANKL/OPG system in human study, vitamin D supplementation was shown to 
suppress osteoclastogenesis by decreasing the production of RANKL and by stimulating 
osteoblast function via alkaline phosphatase (ALP) and bone specific ALP in 
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postmenopausal women (233). The study also suggested that vitamin D is significantly 
involved in RANK/RANKL/OPG system contribute to the treatment of 
osteopenia/osteoporosis. 
Inflammation is the primary factor in various chronic diseases including 
osteoporosis, diabetes mellitus, HIV, RA, IBD, and ankylosing spondylitis, to mention a 
few. Furthermore, there is a link between chronic inflammatory process and serum 
concentration of 25-(OH)D3 in that hypovitaminosis D is observed in many of these 
conditions. A cohort drawn from the Baltimore Hip Studies demonstrated that women 
above 65 years of age with hip fracture were found to have vitamin D deficiency (i.e., 25-
(OH)D3 < 15 ng/mL or 37.5 nmol/L) and elevated IL-6, suggesting the elevation of pro-
inflammatory cytokines may be associated with vitamin D deficiency (234). In a meta-
analysis, serum concentrations of 25-(OH)D3 were found be associated with anti-
inflammatory effects and reduced susceptibility to gingival inflammation (235). 
Studies have shown that prolonged or chronically ill patients had increased bone 
resorption and osteoblast dysfunction (236,237) and had very low serum concentrations 
of 25-(OH)D3 and 1,25(OH)2D3 (236,238,239). Often, lack of vitamin D contributes to 
bone loss in prolonged or chronically ill patients. Studies showed the negative correlation 
between serum 1,25(OH)2D3 and TNF-α may impair 1α-OHase and aggravate its activity 
(238,239). It is known that kidney has the most abundant CYP27B1, which is the gene 
encoding 1α-OHase, thus the dysfunction of 1α-OHase may alter CYP27B1. It would be 
of interest to examine whether chronic inflammation alters CYP27B1 in the tissue, 
especially the kidney, of animals undergoing chronic low-grade inflammation. 
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  While clinical studies have demonstrated an association between inflammation 
and vitamin D, animal studies have been used to further examine this relationship. An in 
vivo study utilizing male Sprague-Dawley rats showed that high intestinal VDR is 
positively correlated with high 1,25(OH)2D3 activity (240). In 1α-OHase (CYP27B1) 
deficient mice, hypocalcemia, secondary hyperparathyroidism, retarded growth, and 
skeletal abnormalities (rickets) were observed in addition to a reduction in CD4+ (helper) 
and CD8+ (cytotoxic) T-lymphocytes. All of these symptoms are associated with 
defective immune function, further supporting that 1α-OHase is essential in skeletal 
homeostasis and regulation of immune function (241). While VDR knockout (KO) mice 
have provided insight into the role of 1,25(OH)2D3 in monocytes/macrophage 
differentiation, monocytes/macrophage differentiation can also occur in the absence of 
VDR, suggesting  monocytes/macrophage can differentiate via other mechanisms (242). 
Another animal study utilizing Sprague-Dawley rats showed that bone expressed 
CYP27B1 and CYP24A1, where CYP24A1 expression is regulated by the synthesis of 
1,25(OH)2D3 in bone and 1,25(OH)2D3 synthesis is associated with bone mineralization 
(243). A dextran sodium sulfate (DSS)-induced mouse model of colitis showed a 5-fold 
decrease in renal CYP27B1 and lower serum 1,25(OH)2D3 (244). These studies indicate 
that chronic inflammatory conditions are associated with low vitamin D and that low 
vitamin D is related to defective immune function.  
The role of LPS, a bacterial toxin, on vitamin D system has been examined in 
vitro utilizing THP-1 cells, a human blood monocytic cell line (223). LPS decreased the 
expression of the VDR protein and down-regulated VDR function. Furthermore, LPS 
impaired 1,25(OH)2D3/VDR  by decreasing the ability of 1,25(OH)2D3 to induced 
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myeloid differentiation into monocytes/macrophages and thus decreasing the ability of 
bacteria killing by innate immune system(223). LPS is a potent stimulator of  
myeloid/macrophage cell production of TNF-α, which involved in chronic inflammatory 
disease such as RA and Crohn’s disease (60). Currently, there are lack of studies 
examining the relationship between LPS and vitamin D metabolites in vivo. The role of 
liver and kidney in the systemic synthesis of 1,25(OH)2D3 is well known, but more 
recently local synthesis has been demonstrated in vitro. In vitro human blood 
mononuclear cells were used to show that monocyte-derived macrophages and monocyte-
derived dendritic cells are able to hydroxylate vitamin D3 into 1,25(OH)2D3. These data 
suggests that local 1,25(OH)2D3 synthesis occurs in myeloid cells of the skin and gut 
(245). Based on this evidence that 1,25(OH)2D3  is synthesized locally in various tissues 
and LPS impairs 1,25(OH)2D3/VDR functions (222, 244), it is reasonable to anticipate 
that LPS-induced chronic inflammation would affect local and/or systemic production of 
vitamin D. 
To date, we are not aware of any studies that have examined the relationship 
between the effects of LPS-induced chronic inflammation on local and systemic vitamin 
D metabolism in vivo. The availability of 1,25(OH)2D3 in tissues is dependent on genes 
encoding vitamin D activating and deactivating enzymes, CYP27B1 and CYP24A1 
(246). Therefore, by examining genes such as CYP27B1 and CYP24A1 in tissues 
especially in liver, spleen, and kidney in vivo we will gain insight into the manner by 
which chronic inflammation affects key hydroxylation enzymes involved in vitamin D 
metabolism and whether chronic inflammation alters vitamin D metabolism. 
  
CHAPTER III 
 
 
METHODOLOGY 
 
Animals and Diet 
  Male C57BL/6J mice used in these experiments (Jackson Laboratory, Bar Harbor, 
ME) were housed in an environmentally controlled animal care facility (22-25°C 
temperature, 12 light:12 dark conditions) and allowed to acclimate for 5-7 days prior to 
the start of the experiments. Mice were fed semi-purified AIN-93M diet and had access 
to reverse osmosis (RO) water ad libitum throughout both studies (47,247). All 
procedures were approved by the Oklahoma Christian University of Arts and Sciences or 
Oklahoma State University Institutional Animal Care and Use Committees. 
 
Study Design for Experiment 1 
  Experiment 1 was designed to evaluate the dose and time response of LPS-
induced low-grade chronic inflammation in the animals using slow-release pellets. 
Twelve-week-old male C57BL/6J mice were randomly assigned to three groups (n= 12 
mice/group) for a study duration of 30 or 90 days: LPS1=0.01 mg LPS /kg body 
weight/day, LPS2=0.1 mg LPS /kg body weight/day), or Control (0 mg LPS/ kg body 
weight/day). Slow-release pellets (Innovative Research of America, Sarosota, FL)  
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LPS (E. coli Serotype 0127:B8; chromatograpically pure, Sigma, St. Louis, MO) were 
implanted subcutaneously in the interscapular region of C57/BL6J mice. The minor 
surgery required that mice be anesthetized using an intramuscular injection of a 
ketamine/xylazine cocktail (10/1 mg/ kg body weight). The site of the incision (i.e., ~2 
cm distal to the interscapular region) was cleaned with 70% ethanol and shaved, and 
sterile forceps were used to make a subcutaneous tunnel for pellet placement. The 
incision was closed with a single suture and mice were allowed to recover under a 
warming light prior to return to their cage. 
 At the end of the 30 and 90 day study period, animals were fasted for 12 hours 
prior to necropsy and then anesthetized (10/1 mg/kg body weight ketamine/xylazine 
cocktail) and sacrificed by exsanguinations via the carotid artery. Blood was collected in 
an EDTA-coated Pasteur pipet and bone specimens were dissected and cleansed of all 
soft tissues. Blood samples were centrifuged at 4000 rpm (3220 x g) at 4°C (Eppendorf 
Centrifuge, Refrigerated Model 5810 R, Hamburg, Germany) for 20 minutes and aliquots 
of plasma were stored at -80°C for later analyses. Soft-tissues (i.e., liver and spleen) were 
immediately frozen in liquid nitrogen. 
  
Study Design for Experiment 2 
  Experiment 2 was designed to investigate the short-term effects of LPS on the 
animals using a daily intraperitoneal (i.p.) injection. Animals were allowed to acclimate 
for 5-7 days and given semi-purified AIN-93M diet prior to the start of the study. Thirty, 
16-week old male C57BL/6J mice were randomly assigned to one of the three 
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groups (n=10 mice/group): control=0 mg LPS /kg body weight/day), LPS1=0.1 mg LPS 
/kg body weight/day or LPS2=0.2 mg LPS /kg body weight/day). In the current study, 
LPS (E. coli Strotype 0127:B8; chromatograpically pure, Sigma, St. Louis, MO Sigma) 
was administered i.p. at approximately the same time each day for 14 consecutive days. 
Body weights were recorded every 3 days throughout the 14-day study period.  
 At the end of the 14-day study period, animals were fasted for 12 hours prior to 
necropsy. Animals were then anesthetized with an intramuscular (i.m.) injection of 
ketamine/xylazine cocktail (10/1 mg/ kg body weight), then body composition, whole 
body BMD, BMC, and bone mineral area (BMA) were determined by dual-energy x-ray 
absorptiometry (DXA) using a GE Lunar PIXImus (GE Medical Systems, Madison, WI). 
The instrument was calibrated according to the manufacturer’s protocol prior to the 
whole body scans and quality control, was demonstrated by a coefficient of variation for 
BMD of <1% and a percent fat +/- 1.0 SD. Animals were then sacrificed by 
exsanguination via the carotid artery. Whole blood was collected in EDTA-coated 
Pasteur pipet and blood smears were prepared. Whole blood samples were centrifuged at 
4000 rpm (3220 x g) at 4°C for 20 minutes and aliquots of plasma were stored at -80°C 
for later analyses. Soft-tissues including the liver, spleen, and kidney were carefully 
isolated, weighed, and immediately placed in liquid nitrogen.  
 
Blood Leukocyte Counts 
  Whole blood was collected at the termination of the study for total and differential 
white blood cell (WBC) counts. 25 µL whole blood was added to microcentrifuge tube 
containing 475 µL of diluting buffer (1:20 dilution), which was prepared with 98 mL 
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deionized water, 1 mL glacial acetic acid, 1 mL 1% gentian violet and the whole 
blood/diluting buffer mixtures were stored at room temperature. Cell counts were 
performed using Neubauer hematocytometer (Bright-Line™, Hausser Scientific, Buffalo, 
NY) under a light-microscope.  
 
Assessment of Bone Microarchitecture using Microcomputed Tomography (µCT) 
  Tibia specimens from Experiment 1 were scanned to determined the alterations in 
trabecular metaphysial and cortical bone microarchitecture using x-ray microcomputed 
tomography (µCT40, SCANCO Medical, Switzerland). For trabecular bone analyses, the 
proximal end of tibia was scanned using an isotropic voxel size of 6 µm in a 2048 x 2048 
matrix to acquire 175 slices (6 µm/slice) distal to the growth plate. Trabecular region was 
analyzed by placing contours beginning 25 slices from the growth plate to incorporate 
only the secondary spongiosa and 100 slices (600 µm) of the trabecular region were 
evaluated within the volume of interest (VOI). The trabecular parameters that were 
assessed included trabecular bone volume expressed per unit of total volume (BV/TV), 
trabecular number (TbN), trabecular thickness (TbTh), trabecular separation (TbSp), 
structure model index (SMI), bone connectivity density (Conn Den), and linear x-ray 
attenuation coefficient (Lin Atten).  
 For cortical analyses, the mid-shaft of the tibia was scanned and 20 slices (120 
µm) were evaluated within the VOI. Cortical bone parameters were assessed at the tibia 
mid-shaft, including cortical thickness, area, and porosity and medullary area.  
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Assessment of Plasma 25-hydroxyvitamin D3 using ELISA 
 Plasma 25-hydroxyvitamin D (25-(OH)D3) was assessed using an enzyme 
immunoassay (ELISA) (Immunodiagnostic Systems, Fountain Hills, AZ). Reagents were 
prepared according to the manufacturer’s protocol. The colorimetric assay was read on a 
Synergy HT multi-detection microplate reader (BIO-TEK, Winooski, VT) and 
absorbance of each well at 450 nm was determine using BIO-TEK KC4 (software version 
3.4). This assay had a sensitivity of 5 nmol/L (i.e. 2 ng/mL) with intra and inter-assay 
coefficients of variation at < 8% and < 10% respectively. 
 
RNA Isolation  
   RNA was isolated from the liver and spleen in Experiment 1 and from the liver, 
spleen, and kidney in Experiment 2. RNA from the liver and kidney were isolated with 
the following protocol. Five to six specimens from each treatment group were randomly 
selected for quantitative real-time polymerase chain reaction (qRT-PCR) analyses. Total 
RNA was isolated from tissues using STAT-60 reagent according to the manufacturer’s 
instructions (Tel-Test, Inc., Friendswood, Texas). In short, the tissue was homogenized in 
the RNA STAT-60 reagent using a polytron homogenizer (VWR PowerMaxTM Advanced 
Homogenizing Systems, 200, Thorofare, NJ). The homogenate was allowed to incubate 
for 5 minutes at room temperature to permit the complete dissociation of 
ribonucleoprotein complexes. Next, 0.2 ml of chloroform per ml of the RNA STAT-60 
was added to the homogenate and shaken vigorously for 15 seconds, and incubate at 
room temperature for 2-3 minutes. The homogenate was centrifuged at 12,000 x g for 15 
minutes at 4°C. Following centrifugation, the aqueous (upper) phase was transferred to a 
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fresh microtube and 0.5 mL isopropanol /mL of STAT-60 was added for RNA 
precipitation. The sample remained on ice for 10 minutes and then centrifuged at 12,000 
x g for 10 min at 4oC. Supernatant was removed and the precipitated RNA pellet was 
washed with 75% ethanol and centrifuged (12,000 x g) for 15 min at 4oC. At the end of 
the procedure, the RNA pellet was briefly air-dried for 2-3 min and then resuspended in 
diethylpyrocarbonate (DEPC)-treated water. The purity of RNA was determined by 
optical density at 260 and 280nm spectophotometry NanoDrop spectrophotometer (ND-
1000, version 3.1.2, Wilmington, DE).  
  In contrast, RNA from the spleen were isolated using a RNA Mini Kit 
(PureLinkTM , Invitrogen Corp., Carlsbad, CA). Reagents were prepared and RNA was 
isolated according to the manufacturer’s protocol. DNAse (PureLinkTM , Invitrogen 
Corp., Carlsbad, CA) was used for on-column digestion of DNA to obtain DNAse free 
total RNA. Similar to the RNA from the liver and kidney, the purity of spleen RNA was 
determined by optical density measured at 260 and 280 on NanoDrop spectophotometer 
(ND-1000, version 3.1.2, Wilmington, DE). 
 
Analysis of Gene Expression using Quantitative Real-time PCR 
  For qRT-PCR analysis, 2 µg RNA was treated with DNase I (Roche, Penzberg, 
Germany) and reverse-transcribed using SuperScript II according to the manufacturer’s 
protocol. qRT-PCR was performed on 7900HT Fast Real-time PCR System (Sequence 
Detection System Version 2.3, Applied Biosystems, Foster City, CA) using SYBR Green 
Chemistry. PCR reactions (10 µl) were performed in duplicate on a 384-well plate with 
10 μl per well. Results were evaluated by the comparative cycle number at threshold (CT) 
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method (User Bulletin No. 2; Perkin-Elmer Life Sciences) using cyclophilin as the 
invariant control gene, Cyclophilin b (247). Primer sequences for genes of interest are 
provided in Table 2.  
 
Statistical Analysis 
  Differences in treatment groups were determined using multiple paired t-tests 
with SAS statistical software (version 9.1.2; SAS Institute Inc., Cary, NC). Data are 
presented as means ± standard error of mean (SEM) and p<0.05 were considered 
statistically significant for all analyses. 
 
 
  
  
44 
 
45 
 
Table 2. Mus musculus Primer Sequences.  
Symbol 
 
       Name Accession 
Number 
            Primer Sequence (5’ → 3’) 
LPS Receptor Complex 
    TLR4 Toll-like receptor 4 NM_021297  F 5’ACTGTTCTTCTCCTGCCTGACA3’  
 R 5’TGATCCATGCATTGGTAGGTAATA3’ 
    CD14 CD14 antigen NM_009841  F 5'GCCGCCACCGCTTCT3’  
 R 5'ACACGTTGCGGAGGTTCA3’ 
Pro-inflammatory Cytokines 
    MIP-1α Macrophage inflammatory 
protein-1alpha 
NM_011337 F 5'TTCATCGTTGACTATTTTGAAACCA3’  
R 5'GCCGGTTTCTCTTAGTCAGGAAa3’ 
    STAT3 Signal transducer and 
activator of transcription 3 
NM_213659 F 5'CCATTGACCTGCCGATGTC3’  
R 5'CTCAGCACCTTCACCGTTATTTC3’ 
    TNF-α Tumor necrosis factor-alpha NM_013693 F 5'CTGAGGTCAATCTGCCCAAGTAC3’  
R 5'CTTCACAGAGCAATGACTCCAAAG3’ 
     IL1-β Interleukin 1 beta NM_008361 F 5'CAACCAACAAGTGATATTCTCCTAG3’  
R 5'GATCCACACTCTCCAGCTGCA3 
     IL-6 
 
Interleukin  6 NM_031168 F 5'GAGGATACCACTCCCAACAGACC3’  
R 5'AAGGCATCATCGTTGTTCATACA3’ 
Anti-inflammatory Cytokines 
     IL-10 Interleukin 10 NM_010548   F 5'GGTTGCCAAGCCTTATCGGA3’ 
  R 5'ACCTGCTCCACTGCCTTGCT3’ 
 
     IL-4 Interleukin 4 NM_021283   F 5'ACAGGAGAAGGGACGCCAT3’ 
  R 5'GAAGCCCTACAGACGAGCTCA3’ 
 
  TGF-β1 Transforming growth factor, 
beta 1 
NM_011577   F 5'GACCCTGCCCCTATATTTGGA3’ 
  R 5'CCGGGTTGTGTTGGTTGTAGA3’ 
Vitamin D Metabolism and Internal Control 
    CYP27A1 Cytochrome P450, family 27, 
subfamily a, polypeptide 1 
NM_024264   F 5'GCCTCACCTATGGGATCTTCA3’ 
  R 5'TCAAAGCCTGACGCAGATG3’ 
 
    CYP27B1 Cytochrome P450, family 27, 
subfamily b, polypeptide 1 
NM_010009   F 5'AGCAGCTCCTGCGACAAGAA3’ 
  R 5'CGTTAGCAATCCGCGAAGCA3’ 
    CYP24A1 Cytochrome P450, family 24, 
subfamily a, polypeptide 1 
 
NM_009996   F 5'TGCCCTATTTAAAGGCCTGTCT3’ 
  R 5'CGAGTTGTGAATGGCACACTT3’ 
     VDR Vitamin D receptor NM_009504   F 5'GGCTTCCACTTCAACGCTATG3’ 
  R 5'ATGCTCCGCCTGAAGAAAC3’ 
 
     Cyclo Cyclophilin b NM_011149   F 5'TGGAGAGCACCAAGACAGACA3’ 
  R 5'TGCCGGAGTCGACAATGAT3’ 
 
   
CHAPTER IV 
 
 
FINDINGS 
 
EXPERIMENT 1: LPS-induced Inflammation via Slow-Release Pellets Over 30 and 
90 Days 
 
Body Weight  
  Animals were weighed every other week and no alterations in body weight 
between treatment groups were observed over the 30- and 90-day study periods (Data not 
shown).  
 
Bone Microarchitecture Properties 
  At 30 days, animals in LPS2 (0.1 mg LPS /kg body weight/day) group exhibited a 
significant decrease in trabecular BV/TV, TbTh, and Conn Denn, and a significant 
increase in SMI. No alterations were observed in TbN and TbSp at this time point. After 
30-days of LPS exposure, cortical porosity of tibial mid-diaphysis was also increased in 
animals from the LPS2 group. The increased in medullary area was the only alteration 
observed in the cortical bone following 90-day LPS exposure (Table 3).  
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Plasma 25-hydroxyvitamin D3 
  Plasma 25-(OH)D3 was assessed to determine the extent to which LPS-induced 
inflammation at 30 and 90 days altered circulating vitamin D. At 30 days, neither LPS1 
nor LPS2 altered plasma 25-(OH)D3 (Figure 2). Unfortunately, plasma 25-(OH)D3 data 
at 90 days was not available due to insufficient sample volume.  
 
Gene Expression Analysis by qRT-PCR 
 At the end of 30 days of LPS exposure using slow-release pellets, hepatic TLR4, 
CD14 and pro- and anti-inflammatory cytokines in both LPS-treated groups were not 
altered (Figure 3 A). Similarly, hepatic genes encoding vitamin D metabolism were not 
altered by 30-day LPS exposure (Figure 3 B). At the end of 90 days of LPS exposure 
using slow-release pellets, IL-10 (pro-inflammatory) and IL-1β (anti-inflammatory) 
cytokines, were significantly down-regulated in LPS1 group (Figure 4A). Hepatic 
CYP27A1 was significantly down-regulated by LPS2 (Figure 4 B).  
  Following 30-day LPS exposure, alterations in inflammatory mediators, genes 
involved in the activation and deactivation of vitamin D and the VDR were assessed in 
the spleen. Splenic TLR4, CD14 and pro- and anti-inflammatory cytokines were not 
altered due to LPS following 30-day (Figure 5 A). Similarly, 30-day LPS exposure did 
not alter splenic genes encoding vitamin D metabolism (Figure 5 B). At the end of 90 
days LPS exposure, LPS2 tended to increase (p = 0.06) splenic TNF-α whereas splenic 
IL-6 was elevated in the LPS1 compared to control groups and an intermediate effect was 
observed on IL-6 in response to LPS 2 (Figure 6 A). Splenic CYP27B1 significantly 
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down-regulated in LPS2 group whereas splenic VDR tended to decrease (p = 0.07) in 
LPS2 group at the end of 90 days LPS exposure (Figure 6 B).  
 
EXPERIMENT 2: LPS-induced Inflammation via Intraperitoneal Injections Over 
14 Days 
 
Body and Tissue Weights 
 The body weights of animals were not significantly altered over the course of the 
14-day study period (Table 4). No alterations were observed in the spleen and kidneys 
weights of animals in the two LPS-treated groups compared to controls (Table 4).   
 
Bone Density and Composition 
 DXA scans were performed prior to necropsy to determine if the low grade 
inflammation induced by LPS injections affected bone density and composition. Whole 
body bone parameters including, BMD, BMC, and BMA were not altered following 14-
day of LPS treatment which may have been anticipated due to the short study duration. In 
the case of body composition, lean and fat mass, and percent body fat remained 
unchanged at the end of the 14-day study period (Table 5).   
 
Blood Leukocyte Counts 
  Blood leukocytes were determined light-microscopy to assess if LPS injections 
altered the systemic inflammatory state. Mean total white blood cells (WBC) (n = 8- 10 
per group) were: Control 4.30 x 106 ± 0.94, LPS1 4.74 x 106 ± 0.58, and LPS2 4.00 x 106 
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± 0.36. There was no significant difference in the WBC among the three different LPS 
treatment groups. WBC differentials showed LPS1 (0.1 mg LPS /kg body weight/day) 
significantly increased monocytes after 14 days of LPS administration (Figure 7 A). No 
alterations were observed in percentage of neutrophils, neutrophils/monocytes ratios 
(Figure 7 B and C), eosinophils and basophils for the two LPS-treated groups. 
 
Plasma 25-hydroxyvitamin D3 
 The dose-dependent effects of LPS exposure over time were assessed in the 
circulating 25-(OH)D3. Plasma 25-(OH)D3 of animals receiving LPS1 and LPS2 were 
significantly elevated compared to controls. No significant difference was found in 
plasma 25-(OH)D3 of LPS1 and LPS2 (Figure 8).  
 
Gene Expression Analysis by qRT-PCR 
  CD14 and TLR4 gene expression was assessed to determine if an LPS response 
occurred following 14-day LPS administration. Hepatic CD14 and TLR4 gene expression 
was significantly up-regulated in LPS1 and LPS2 compared to controls, confirming the 
LPS response (Figure 9 A). The pro-inflammatory macrophage inflammatory protein-1α 
(MIP-1α) and downstream effector STAT3 were not altered with either dose of LPS 
(Figure 9 A). 
To assess the inflammatory response after 14 days of LPS injection, hepatic gene 
expression of TNF-α, IL-1β, IL-6 (pro-inflammatory) and IL-10, IL-4, and TGF-β (anti-
inflammatory cytokines) were evaluated. Hepatic IL-10 and TGF-β expression was 
significantly up-regulated in LPS2 compared to controls (Figure 9 B). No significant 
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alteration was seen in hepatic TNF-α, IL-1β, IL-6, and IL-4 expression (Figure 9 B). 
Genes involved in vitamin D metabolism (CYP27A1 and VDR) in hepatic tissue were 
assessed following 14-day LPS treatment and no significant alterations were observed 
(Figure 9 C).  
The inflammatory response to LPS in the spleen was assessed by the expression 
of TLR4, CD14, TNF-α, IL-1β, IL-6, and IL-10. Splenic IL-1β tended to decrease (p = 
0.05) in LPS1 group and no significant alterations were observed in LPS receptor 
complex, and the other pro- and anti-inflammatory cytokines analyzed (Figure 10 A). 
Splenic VDR expression tended to be decreased (p=0.08) with LPS2 (Figure 10 B). 
  In addition to the determining the influence of 14 days of LPS on liver and spleen 
gene expression, kidney, another major site of vitamin D metabolism and activity was 
examined. The pro-inflammatory cytokine IL1-β expression in the kidney was up-
regulated in LPS1 but not in LPS2 (Figure 11 A. LPS1 and LPS2 significantly down-
regulated kidney CYP27B1 expression compared to controls, however, kidney CYP27B1 
expression was not different between the two LPS-treated groups (Figure 11 B). 
Furthermore, kidney CYP24A1 expression significantly elevated in LPS1 compared to 
controls but not in LPS2 suggesting that LPS1 may increase the catabolism of 
1,25(OH)D3 (Figure 11 B). 
 
 
Table 3. Trabecular and Cortical Bone Microarchitectural Properties of the Proximal Tibia Metaphysis and the Tibia Mid-
diaphysis following 30 and 90 Days of LPS Treatment.  
 30 days 90 days 
 Parameters Control LPS 1 LPS 2 Control LPS 1 LPS 2 
Trabecular Bone       
BV/TV (%) 19.9 ± 1.7a 14.6 ± 2.5a 11.6 ± 0.9b 16.9 ± 1.5 18.1 ± 1.7 13.0 ± 2.3 
TbN (1/mm3) 5.33 ± 0.09a 4.67 ± 0.30b 4.92 ± 0.13a 4.42 ± 0.19a 5.05 ± 0.12b 4.53 ± 0.10a 
TbTh (mm) 0.058 ± 0.003a 0.049 ± 0.003b 0.045 ± 0.002b 0.059 ± 0.003a 0.055 ± 0.003a 0.049 ± 0.003b 
TbSp (mm) 0.18 ± 0.04a 0.22 ± 0.02b 0.20 ± 0.01a 0.23 ± 0.01a 0.19 ± 0.01b 0.22 ± 0.01a 
       
Cortical Bone       
Cort Th (mm) 0.25 ± 0.11 0.24 ± 0.01 0.23 ± 0.00 0.24 ± 0.01 0.24 ± 0.01 0.24 ± 0.01 
Cort Area (mm2) 0.86 ± 0.04 0.81 ± 0.05 0.72 ± 0.01 0.81 ± 0.04 0.83 ± 0.03 0.83 ± 0.05 
Medullary Area (mm2) 0.034 ± 0.003 0.037 ± 0.002 0.037 ± 0.001 0.029 ± 0.003a 0.037 ± 0.001b 0.035 ± 0.001b 
Cort Porosity (%) 3.8 ± 0.2a 4.5 ± 0.3b 4.8 ± 0.2b 3.5 ± 0.4 4.3 ± 0.2 4.1 ± 0.2 
Control (0 mg LPS /kg body weight/day), LPS 1 (0.1 mg LPS /kg body weight/day), and LPS 2 (0.2 mg LPS /kg body weight/day) on 
mean body weight of animals. Values for a given parameter that do not share the same superscript at 30 or 90 days are statistically 
different (p < 0.05). Values are mean ± SE, (n = 12/ group).  
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Table 4. Body and Tissue Weights following 14 Days of LPS Treatment.  
 Control (n = 10) LPS 1 (n=8) LPS 2 (n = 10) 
Body Weight (g)    
     Baseline 27.94 ± 0.52 27.59 ± 0.56 28.55 ± 0.56 
     Final 26.73 ± 0.58 25.94 ± 0.69 27.63 ± 0.61 
 
Tissue Weight (g)    
     Spleen 0.08 ± 0.01 0.08 ± 0.01 0.09 ± 0.00 
     Kidney 0.29 ± 0.01 0.30 ± 0.01 0.31 ± 0.01 
Control (0 mg LPS /kg body weight/day), LPS 1 (0.1 mg LPS /kg body weight/day), and 
LPS 2 (0.2 mg LPS /kg body weight/day) on mean body weight of animals. Values are 
mean ± SE.  
 
 
  
52 
 
Table 5. Bone Densitometry and Body Composition Parameters of Mice following 14 
days of LPS Treatment. 
Parameters Control LPS 1 LPS 2 
Bone Densitometry 
BMA (cm2) 12.381 ± 0.35 11.924 ± 0.39 12.158 ± 0.16 
BMC (g) 0.706 ± 0.03 0.662 ± 0.02 0.681 ± 0.01 
BMD (g/cm3) 0.056 ± 0.001 0.055 ± 0.000 0.055 ± 0.000 
Body Composition 
Lean (g) 20.32 ± 0.704 19.66 ± 0.676 21.88 ± 0.561 
Fat (g) 5.84 ± 0.2 5.61 ± 0.1 5.60 ± 0.2 
Fat (%) 22.36 ± 0.7 22.34 ± 0.7 20.34 ± 0.5 
Control (0 mg LPS /kg body weight/day), LPS1 (0.1 mg LPS /kg body weight/day), and 
LPS2 (0.2 mg LPS /kg body weight/day). Values are mean ± SE. 
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Figure 2.  
  
Plasma 25-(OH)D3 following 30 Days of LPS Treatment. Control (0 mg LPS/ kg body 
weight/day), LPS 1 dose (0.01 mg LPS /kg body weight/day), and LPS 2 (0.1 mg LPS /kg 
body weight/day). Bars represent the mean ± SE for each treatment group (n=6-7/ group). 
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Figure 3.  
 
 
 
 
Hepatic Gene Expression Associated with (A) CD14, TLR4 and Inflammatory Mediators, 
and (B) CYP27A1, CYP27B1, and VDR following 30 Days of LPS Treatment. Control 
(0 mg LPS/ kg body weight/day), LPS 1 dose (0.01 mg LPS /kg body weight/day), and 
LPS 2 (0.1 mg LPS /kg body weight/day). Bars represent the mean ± SE for each 
treatment group (n= 4-5/group). 
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Figure 4.   
 
 
 
 
Hepatic Gene Expression Associated with (A) CD14, TLR4 and Inflammatory Mediators, 
and (B) CYP27A1, CYP27B1, and VDR following 90 Days of LPS Treatment. Control 
(0 mg LPS/ kg body weight/day), LPS 1 dose (0.01 mg LPS /kg body weight/day), and 
LPS 2 (0.1 mg LPS /kg body weight/day). Bars represent the mean ± SE for each 
treatment group. Bars for a given gene without superscript letter are not statistically 
different (p < 0.05) (n= 4- 6/group). 
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Figure 5.  
 
 
 
 
Splenic Gene Expression Associated with (A) Inflammatory Mediators, and (B) 
CYP27A1, CYP27B1, CYP24A1, and VDR following 30 Days of LPS Treatment. 
Control (0 mg LPS/ kg body weight/day), LPS 1 dose (0.01 mg LPS /kg body 
weight/day), and LPS 2 (0.1 mg LPS /kg body weight/day). Bars represent the mean ± SE 
for each treatment group. Bars for a given gene without superscript letter are not 
statistically different (p < 0.05) ( n = 4- 5/ group).  
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Figure 6.  
  
 
 
 
Splenic Gene Expression Associated with (A) Inflammatory Mediators, and (B) 
CYP27A1, CYP27B1, CYP24A1, and VDR following 90 Days of LPS Treatment. 
Control (0 mg LPS/ kg body weight/day), LPS 1 dose (0.01 mg LPS /kg body 
weight/day), and LPS 2 (0.1 mg LPS /kg body weight/day). Bars represent the mean ± SE 
for each treatment group. Bars for a given gene without superscript letter are not 
statistically different (p < 0.05) (n = 4- 5/group). 
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Figure 7.  
 
 
 
Alterations in Percentage of (A) Monocytes, (B) Neutrophils, (C) Neutrophils/Monocytes 
Ratios After 14 Days of LPS Treatment. Control (0 mg LPS /kg body weight/day), LPS 1 
(0.1 mg LPS /kg body weight/day), and LPS 2 (0.2 mg LPS /kg body weight/day). Bars 
represent the mean ± SE for each treatment group. Bars without superscript letter are not 
statistically different (p < 0.05) (n=4 mice/group).  
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Figure 8.  
 
Plasma 25-(OH)D3 following 14 Days of LPS Treatment. Control (0 mg LPS /kg body 
weight/day), LPS 1 (0.1 mg LPS /kg body weight/day), and LPS 2 (0.2 mg LPS /kg body 
weight/day). Bars represent the mean ± SE for each treatment group. Bars that do not 
share the same superscript letter are statistically different (p < 0.05) (n=8-10 
mice/group).  
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Figure 9.  
 
 
 
Hepatic Gene Expression Associated with (A) TLR4, CD14, MIP-1α, and STAT3, (B) 
Inflammatory Mediators, and (C) CYP27A1 and VDR following 14 Days of LPS 
Treatment. Control (0 mg LPS /kg body weight/day), LPS 1 (0.1 mg LPS /kg body 
weight/day), and LPS 2 (0.2 mg LPS /kg body weight/day). Bars represent the mean ± SE 
for each treatment group. Bars of a given gene that do not share the same superscript 
letter are statistically different (p < 0.05) (n = 5- 6/group).  
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Figure 10.  
 
 
 
 
Splenic Gene Expression Associated with (A) TLR4, CD14, and Inflammatory 
Mediators, and (B) CYP27A1, CYP27B1, CYP24A1, and VDR following 14 Days of 
LPS Treatment. Control (0 mg LPS /kg body weight/day), LPS 1 (0.1 mg LPS /kg body 
weight/day), and LPS 2 (0.2 mg LPS /kg body weight/day). Bars represent the mean ± SE 
for each treatment group. Bars of a given gene without superscript letter are not 
statistically different (p < 0.05) (n = 6 per group).  
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Figure 11.  
 
 
 
 
Renal Gene Expression Associated with (A) Inflammatory Mediators and (B) CYP27B1, 
CYP24A1, and VDR following 14 Days of LPS Treatment. Control (0 mg LPS /kg body 
weight/day), LPS 1 (0.1 mg LPS /kg body weight/day), and LPS 2 (0.2 mg LPS /kg body 
weight/day). Bars represent the mean ± SE for each treatment group. Bars of a given gene 
that do not share the same superscript letter are statistically different (p < 0.05) (n = 5- 
6/group). 
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CHAPTER V 
 
 
DISCUSSION 
 
The overall objective of this study was to examine the effects of low dose LPS 
administration in vivo on inflammatory pathways and gene expression of VDR and key 
hydroxylation enzymes involved in vitamin D metabolism. Our laboratory previously 
reported that LPS delivered via slow-release pellets was shown to induce a low-grade 
chronic inflammation that resulted in bone loss in skeletally mature rat and mouse 
(47,48). Ninety days of LPS exposure in male Sprague-Dawley rats was associated with a 
decrease in femoral and vertebral BMD, with greater bone loss in the trabecular 
compared to the cortical regions (47). Additionally, fibrous tissue surrounding the 
coronary arterioles was observed, consistent with microvascular disease. Elevation of 
peripheral neutrophils and monocytes determined by differential white blood cell counts 
indicated that a continuous inflammatory response had occurred. Similar bone and 
vascular pathology were observed in C57BL/6J mice in a shorter-time period (i.e. 28 
days). 
In the current study, we were interested in determining if alterations in vitamin D 
metabolism were involved in the relationship between LPS, bone, and vascular 
pathology. To begin to explore this relationship, we first examined the inflammatory 
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response looking at TLR4, CD14 and pro- and anti-inflammatory cytokines in the liver 
and spleen. Studies have shown that LPS stimulates pro-inflammatory responses of 
Kupffer cells or resident hepatic macrophages, enhances TLR4 signaling and contributes 
to in vivo hepatic inflammation and injury (107,248-250). These studies suggested that 
LPS acts via TLR4 to initiate inflammatory response. Thus we wanted to verify the 
inflammatory response by examining TLR4 expression. We have shown here that in the 
hepatic tissue, 14 days of low dose LPS injection resulted in up-regulation of IL-10 and 
TGF-β, which coincided with increased CD14 and TLR4 gene expression. The LPS-
induced up-regulation of hepatic CD14 in our study is similar to the response observed in 
human monocytes, where CD14 was shown to be up-regulated by LPS (251). In vivo LPS 
delivered via osmotic mini-pumps was shown to up-regulate hepatic IL-10 and TGF-β, 
which was consistent with our observation in the 14 days of low dose LPS injection study 
(252). LPS was shown dose-dependently increased TNF-α in isolated Kupffer cells from 
male Sprague-Dawley rats (107), however, hepatic TNF-α mRNA expression was not 
increased in our study. The lack of changes in hepatic TNF-α, IL-1β and IL-6 mRNA 
levels may in part, be due to the suppression of IL-10, which was significantly up-
regulated in hepatic tissue along with TGF-β in the low dose LPS group. The up-
regulation of IL-10 has been shown to protect mice from septic shock (253). Pre-
treatment of IL-10 in vivo was shown to reduce the LPS-induced release of TNF-α, 
verifying the efficacy of IL-10 in suppressing TNF-α production (254). Similarly TGF-β 
was shown to inhibit in vitro the macrophage response to LPS by down-regulating CD14 
(255).  
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Furthermore, pro- and anti-inflammatory cytokines exhibit different peak and 
nadir times, thus choosing a time point that coincided with the nadir time would yield low 
gene expression levels. In vivo study of mice administered a single dose of 5 mg/kg LPS 
has shown that, circulating TNF-α and IL-10 as well as their hepatic mRNA expression 
peaked at 1.5 hour following the injection. After a nadir at 6 hour, a second peak was 
shown in 8 and 12 hours (256). At 24 hours, circulating TNF-α was decreased following 
administration of a single dose of 9 mg/kg LPS (257). In terms of hepatic IL-6 
expression, it was increased within 2 hours after a single dose of LPS injection (5 mg/kg) 
and declined to normal level 8 hours post-injection (258). Keeping in mind that our 
samples were procured and analyzed 20 hours post injection, we might not observed an 
increase in hepatic TNF-α and IL-6 mRNA expression. Furthermore, we did not measure 
the circulating TNF-α and its expression in the supernatant, however, we measured its 
expression in the tissue.  
In addition to the alterations in gene expression in the liver, we also evaluated the 
response of the spleen, a tissue that tends to have high numbers of monocytes (62,202). 
Monocytes/macrophages were shown to express CYP27B1 (62) and are the main 
producers of TNF-α in normal mice (257). Monocytes differentiate into macrophages, 
which then perform scavenging activities and at the same time enhance the release of 
inflammatory mediators. This response was demonstrated in vitro, in LPS-stimulated 
splenic macrophages isolated from mice in which, LPS activated macrophages and 
enhanced TNF-α release (263). We found that in response to 14 days of LPS 
administration via intraperitoneal injection, the only splenic inflammatory mediator that 
tended to be increased was IL-1β in the group receiving the low dose of LPS. Thirty and 
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ninety days of LPS exposure did not alter splenic TNF-α, IL-1β, however, at 90 days, 
splenic IL-6 was increased by LPS exposure. The low level of expression is likely related 
to the variability of time response of inflammatory mediators after LPS administration.  
To investigate how LPS influenced vitamin D metabolism, we examined genes 
associated with hydroxylation with CYP27A1, CYP27B1, and CYP24A1 of vitamin D 
activation and deactivation and the expression of VDR in the liver, spleen, and kidney. 
The hepatic CYP27A1 is the major gene that encodes for 25-OHase, which is required 
for the hydroxylation of vitamin D3 to 25-(OH)D3 which is the most abundant circulating 
form of vitamin D. Fourteen days and 30 days of LPS-induced chronic inflammation did 
not alter hepatic CYP27A1, however, at 90 days its expression level was decreased in 
higher dose of LPS. This may imply that hepatic CYP27A1 would be decreased after an 
extended period of exposure time. The short-term effect (i.e. within hours) of LPS on 
hepatic sterol 27-hydroxylase (CYP27A1) was demonstrated in Syrian hamsters and 
C57BL/6J mice, where LPS was shown to down-regulate the activity and hepatic mRNA 
expression of CYP27A1 in Syrian hamsters at 24 hours and in C57BL/6J mice at 16 
hours (264). Pramanik and colleagues (223) demonstrated that LPS down-regulated VDR 
and impaired vitamin D function in human THP-1 blood monocytes at 24 hours. 
However, our results from the spleen showed that 14 and 90 days LPS administration 
tended to decrease splenic VDR, but no changes were observed at 30 days. At 90 days 
CYP27B1 expression was decreased in the spleen. These data suggest that low doses of 
LPS do not alter local vitamin D metabolism in the spleen at 30 days, but after 90 days 
some changes had occurred. 
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The kidney was also examined due to its major role in the synthesis of 
1,25(OH)2D3 (CYP27B1) and the catabolism of 1,25(OH)2D3 and 25-(OH)D3 
(CYP24A1). We found that the up-regulation of renal IL-1β coincides with the unaltered 
renal VDR expression. At 14 days, gene expression for CYP27B1 in the kidney was 
down-regulated, indicating low doses of LPS may suppress gene expression in a 
relatively short period of time. Additionally, renal CYP24A1, the intrinsic mechanism by 
which 1,25(OH)2D3 and 25-(OH)D3 are catabolized, was up-regulated. Bland and 
colleagues (265) showed a significant increase of 24-OHase activity in human cortical 
collecting duct cells following incubation with LPS, coincides with the expression of 
TLR4 and CD14. Although we did not examine renal TLR4 and CD14, we verified the 
inflammatory response by examining hepatic TLR4, CD14, pro- and anti-inflammatory 
cytokines expression. We observed a significant increase in CYP24A1 expression 
following 14 days of LPS administration. At the 14-day time point, although we observed 
that renal CYP24A1was increased in low dose LPS, its increase did not decrease plasma 
25-(OH)D3. It seems that CYP24A1, at least at this time point, did not affect plasma 25-
(OH)D3. However, the decrease in CYP27B1 gene expression at 14 days may be due to 
the direct effect of LPS. It is unclear what the response would be to LPS exposure longer 
than 30 days. Unfortunately, we were not able to determine if the alterations in gene 
expression occurred in response to 30 and 90 days of LPS administered via LPS pellets 
due to the fact that kidney samples were not procured at the time of necropsy. The 
relationship between chronic LPS exposure (i.e., ≥30 days) to vitamin D metabolism in 
the kidney remains to be elucidated.  
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In addition to examining the changes in tissue level, a classical approach was used 
to determine the effects of LPS on circulating vitamin D. Fourteen days of LPS 
administration increased plasma 25-(OH)D3, but no alteration were observed with the 
pellets at 30 days. Plasma 25-(OH)D3 seemed to not to be affected by  the up-regulation 
of CYP24A1 at 14 days. This may perhaps be due to the majority of CYP24A1 being 
used to catabolize plasma 1,25(OH)2D3 instead of plasma 25-(OH)D3. However, this is 
speculation on our part and unfortunately data for plasma 1,25(OH)2D3 is not available at 
this time. The increase in plasma 25-(OH)D3 may also attributed to the unaltered hepatic 
CYP27A1, which is involved in converting vitamin D3 to 25-(OH)D3. CYP27A1 was 
strongly express in the macrophages derived from human blood monocytes (245), thus 
local expression of CYP27A1 in the macrophages within the liver may contribute to the 
increased plasma 25-(OH)D3. Mice with inactivated CYP27A1 had normal plasma 
1,25(OH)2D3, indicating CYP27A1 was not critical for plasma 1,25(OH)2D3 (266). When 
LPS was infused (0.0, 0.5, 1.0, and 1.5 µg/kg body weight) into dairy cows over a period 
of 100 minutes, both plasma 25-(OH)D3 and 1,25(OH)2D3 were not affected by 
intravenous LPS infusion, however, when comparing all other doses of LPS combined to 
controls plasma 1,25(OH)2D3 tended to decrease (267). This study showed that LPS at 
minimal doses did not decrease plasma 25-(OH)D3 in vivo. Similarly, we may anticipate 
that minimal doses of LPS may not decrease plasma 25-(OH)D3 in mice. However the 
mechanism of how LPS influence plasma 25-(OH)D3 and 1,25(OH)2D3  remains to be 
elucidated.  
Based on the results of these studies, we conclude that low grade chronic 
inflammation induced by LPS influences vitamin D metabolism over time. Further 
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studies are needed to better characterize these effects over time utilizing either the slow 
release pellet system or injection and to further investigate the mechanisms involved. 
 
 
 
CHAPTER VI 
 
 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 
Summary  
 The purpose of our study was to examine the effects of low dose LPS 
administration in vivo on inflammatory pathways and gene expression of VDR and key 
hydroxylation enzymes involved in vitamin D metabolism. In experiment 1, twelve-
week-old male C57BL/6J mice (n=12/group) were assigned to three doses of LPS (0, 
0.01, 0.1 mg LPS /kg body weight/day) delivered via slow-release pellets for 30 or 90 
days. In experiment 2, sixteen-week-old male C57BL/6J mice (n=30) were administered 
LPS (0, 0.1, 0.2 mg LPS /kg body weight/day i.p.) for 14 days. We showed that two 
weeks of LPS exposure did not produce significant changes in pro-inflammatory 
cytokines but increased anti-inflammatory cytokines IL-10 and TGF-β and TLR4 and 
CD14 in the liver. Inflammatory mediators in the liver did not change at 30 days but IL-
1β and IL-10 were decreased with higher LPS dose at 90 days. Two weeks low dose LPS 
tended to increase (p = 0.05) splenic IL-1β and significantly increased renal IL-1β. No 
changes were observed in inflammatory mediators after 30 days of LPS exposure, 
however, low dose LPS significantly increased IL-6 and higher LPS dose tended to 
increase (p = 0.06) TNF-α in 90 days. In terms of the effects of LPS on the key vitamin D 
hydroxylation enzymes, no changes were observed in the liver and the spleen after two  
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weeks of LPS administration, however, splenic VDR tended to decrease (p = 0.08) in 
higher LPS dose. After two weeks of LPS administration, both doses of LPS suppressed 
renal CYP27B1 while lower LPS dose enhanced renal CYP24A1. Thirty days of LPS 
exposure did not alter any key vitamin D hydroxylation enzymes and VDR expressions in 
the liver and spleen, however higher LPS dose decreased hepatic CYP27A1 and splenic 
CYP27B1 and tended to decrease (p = 0.07) splenic VDR after 90 days of LPS exposure. 
At two weeks, plasma 25-(OH)D3 increased in low dose of LPS but did not change after 
30 days LPS exposure. These data suggest that LPS-induced low grade chronic 
inflammation alter gene expression of VDR and key hydroxylation enzymes involved in 
vitamin D metabolism over time.  
 
Conclusions   
Based on the results of these studies, we conclude the following for each of the 
hypotheses tested:  
1. Over time (i.e., 30 and 90 days) inflammation induced with increasing dose of 
LPS in adult C57BL/6J mice will alter genes encoding for vitamin D activating 
and deactivating enzyme, 1-α-hydroxylase (CYP27B1) and 24-hydroxylase 
(CYP24A1), in hepatic tissue.   
  This hypothesis was rejected due to the lack of an effect of either dose of 
LPS on hepatic CYP27B1and CYP24A1 at 30 and 90 days. It is important to note 
that CYP27B1 and CYP24A1expression was not abundant in the liver. CYP27B1 
is required for the 25-hydroxylation of 25-(OH)D3 to 1,25(OH)2D3 while 
CYP24A1is required to catalyze 1,25(OH)2D3 to 1,24,25(OH)3D3 or 25-(OH)D3 
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to 24,25(OH)2D3 (1) and both are highly expressed in the kidney (2). Therefore, 
having access to kidney samples and being able to examine the expression of 
genes encoding for these enzymes in the kidney instead of the liver in future 
experiments would enable us to determine the effects of chronic inflammation 
induced by LPS on the vitamin D activating and deactivating enzymes.  
 
2.   LPS will dose dependently reduce circulating vitamin D metabolites in adult male 
C57BL/6J mice over time.  
  We rejected this hypothesis because the circulating vitamin D metabolite 
(i.e., 25-(OH)D3) was not affected by increasing dose of LPS following 30 days 
exposure. The inability to evaluate plasma 25-(OH)D3 at 90 days prevented us 
from determining if the decrease in hepatic CYP27A1 expression, which is 
required to synthesize circulating 25-(OH)D3 (3-6), would have resulted in 
decreased circulating 25-(OH)D3 at this time point. 
 
3.    LPS-induced pro-inflammatory cytokine (e.g. TNF-α and IL-6) will down-
regulate genes encoding vitamin D activating and deactivating enzymes in the 
spleen, a monocyte rich tissue, in adult male C57BL/6J mice.  
  This hypothesis is accepted because splenic CYP27B1 and VDR were 
down-regulated to some degree by the higher LPS dose at 90 days, suggesting that 
LPS at this dose has modest effects on local splenic CYP27B1 expression. These 
effects were seen in 90 days of LPS2 exposure and corresponded to the increased 
(p = 0.07) of splenic TNF-α and an intermediate effect of IL-6.    
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With regard to Experiment 2, the following hypotheses were tested: 
1.   Short-term (i.e., 14-days) induced inflammation with increasing dose of LPS ( 0, 
0.1, 0.2 mg LPS /kg body weight/day) in adult C57BL/6J mice will alter genes 
encoding for vitamin D activating and deactivating enzyme, 1-α-hydroxylase 
(CYP27B1) and 24-hydroxylase (CYP24A1), in hepatic and renal tissues.  
  As a result of Experiment 2, we rejected this hypothesis. Fourteen-days 
LPS treatment did not alter hepatic CYP27B1 and CYP24A1, which may be 
suppressed by the up-regulation of IL-10 and TGF-β. The low abundance of these 
genes in the hepatic tissue may not be detectable by qRT-PCR. However, renal 
CYP27B1 was significantly decreased in LPS1 following two-week LPS 
treatment which may contribute to the up-regulation of renal IL-1β and 
CYP24A1. As to whether which of these genes (renal IL-1β and CYP24A1) are 
the major mediators of these effects will require further investigation.   
 
2.  LPS will dose dependently reduce circulating vitamin D metabolites in adult male 
C57BL/6J mice over time.  
  We rejected this hypothesis because circulating 25-(OH)D3 was 
significantly increased in LPS1 group and no changes were seen in LPS2 (0.2 mg 
LPS /kg body weight/day) group. Circulating 25-(OH)D3 is synthesize by 
CYP27A1, thus the conservation of hepatic CYP27A1 may contribute to the 
increased circulating 25-(OH)D3 in LPS1 group.  
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3.  LPS-induced pro-inflammatory cytokine (e.g. TNF-α) will down-regulate genes 
encoding vitamin D activating and deactivating enzymes in the spleen, a 
monocyte rich tissue, in adult male C57BL/6J mice.   
  This hypothesis was rejected because TNF-α did not seem to down-
regulate vitamin D activating and deactivating enzymes in the spleen at 14 days. 
However, VDR expression tended to be decreased (p=0.08) with the higher LPS 
dose (LPS2). Experiment 2 suggests that LPS1 administered via intraperitoneal 
injection for 2 weeks suppressed renal CYP27B1 gene expression and has modest 
effects on VDR expression, indicating chronic inflammation affects vitamin D 
metabolism at the gene level.  
 
Future Directions  
   To better understand if the effects of LPS on vitamin D metabolism play a role in 
the bone loss associated with chronic inflammation, future studies should be designed to 
examine alterations in gene expression in renal tissue and plasma 1,25(OH)2D3 over time 
(e.g. 4 and 6 weeks). Previously, we observed bone loss in the animals after 30 and 90 
days of LPS exposure, but could not determine if there were alterations in gene 
expression associated with vitamin D metabolism in the kidney or changes in circulating 
vitamin D metabolites due to the fact that renal tissue and plasma samples were not 
available. Utilizing a model of LPS exposure over time may allow us to correlate the 
changes in gene expression that occur in the kidney and systemic vitamin D status to 
bone loss.   
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Additionally, a KO mouse model should be used to examine if the alterations in 
vitamin D metabolism are involved in the relationship between bone loss, and key pro-
inflammatory cytokines such as TNF-α. For example, a TNF-α KO mouse implanted with 
slow-release pellets or given intraperitoneal LPS would provide information if TNF-α is 
the major pro-inflammatory cytokine that causes bone loss in trabecular and cortical bone 
and decreases gene expression of vitamin D hydroxylation enzymes in bone and soft-
tissues. Additionally, this would allow us to examine whether TNF-α is causing a 
decrease in plasma 25-(OH)D3 by down-regulating hepatic CYP27A1 and plasma 
1,25(OH)2D3 by down-regulating renal CYP27B1, when comparing plasma 25-(OH)D3 
and 1,25(OH)2D3 between TNF-α KO and wild type mice. A CYP27B1 KO mouse model 
may not be an appropriate model to address the question of our study because it is known 
that CYP27B1 KO mice experience skeletal abnormalities and decrease immune 
function. Exposing the animals to LPS may exacerbate bone loss and may eventually 
shorten the lifespan of the animals.   
In experiment 2, we utilized only one time point (i.e., 2 weeks) to examine the 
effects of low dose LPS administration in vivo on inflammatory pathways and vitamin D 
activating and deactivating enzymes and VDR gene expression. Furthermore, we do not 
know if 2 weeks of LPS treatment causes bone loss. To further confirm if LPS treatment 
alters gene expression of vitamin D hydroxylation enzymes and bone metabolism, we 
should utilize additional time points such as 4 and 6 weeks in the same model (i.e., 
administering LPS i.p.).   
The effects of LPS on vitamin D and bone metabolism should be examined 
utilizing vitamin D insufficient animals. Exposing the vitamin D insufficient animals and 
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normal animals with different doses of LPS via slow-release pellets or injection at 
various time points (e.g. 2, 4, 6 weeks), would allow us to examine whether over time 
chronic inflammation decrease gene expression of vitamin D hydroxylation enzymes and 
increase bone loss. We may also examine whether vitamin D insufficiency exacerbate 
inflammatory conditions, which in turn, further decrease vitamin D status. Furthermore, 
the effects of LPS-induced inflammation on local synthesis of vitamin D may be 
compared between vitamin D insufficient and normal animals by examining CYP27B1 in 
bone and in monocytes from spleen.  
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Oklahoma State University 
Institutional Animal Care and Use Committee (IACUC) 
 Protocol Expires 7/31/2011 
Date : Tuesday, October 28, 2008 Animal Care and Use Protocol (ACUP)   HE-08-3 
Proposal  Alterations in Vitamin D Metabolism with Chronic inflammation and the Resulting  
 Effects on Bone 
Principal  
Investigator: 
Brenda J. Smith 
Nutritional Sciences 
301 HES 
Campus 
Reviewed and  
Processed as: Special Review Modification 
Approval Status Recommended by Reviewer(s) : Approved 
The requested modifications in personnel and change in study design have been approved. The protocol is  
amended to test the effects of two doses of LPS without the TNF-Alpha inhibitor. The first dose is 0.1 mg LPS/kg body  
weight/d and the additional dose is 0.2 mg LPS/kg body weight/d.  Two researchers have been added to the personnel list: 
Lawrance Chandra and Weiyu Jiang. 
Signatures  
 Tuesday, October 28, 2008 
Dr. Charlotte Ownby, IACUC Chair Date 
cc:  Department Head, Human Environmental Sciences 
 LAR 
Approvals are valid for three calendar years, after which time a request for renewal must be submitted.  Any modifications
 to the research project, course, or testing procedures must be submitted for review and approval by the IACUC, prior to  
initiating any changes.  Modifications do not affect the original approval period.  Modification approvals are valid for the  
duration of the protocol approval (see protocol expiration date).  Approved projects are subject to monitoring by the  
IACUC.  OSU is a USDA registered research facility and maintains an Animal Welfare Assurance document with the Public 
Health Service Office of Laboratory Animal Welfare, Assurance number AA3722-01.   
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The objective of this study was to examine the effects of low dose LPS in vivo on 
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should further explore how LPS alters renal gene expression of cytochrome P450 
enzymes involved in vitamin D metabolism over time.
ADVISER’S APPROVAL:   Dr. Brenda J. Smith 
 
  
 
